EBM　血液疾患の治療　2019-2020

出版社： 中外医学社
著者：
発行日： 2018-10-15
分野： 臨床医学：内科  >  血液
ISBN： 9784498225145
電子書籍版： 2018-10-15 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

13,750 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

13,750 円(税込)

購入する

商品紹介

血液疾患における諸問題をいかに解決し、対応すべきか、最新のエビデンスをもとに解説したレファランス。治療に必須の知見を「序論、指針、エビデンス、根拠となった臨床研究の問題点と限界、患者に適応する際の注意点、コメント」の順に紹介し、今日の時点における最新の治療法、考え方だけでなく、現場で判断に迷うような事柄・問題点に指針を与えるものとなっている。

目次

  • I．造血器腫瘍の新しい分類
    　1．WHO分類改訂第4版（2017）における骨髄系腫瘍
    　2．WHO分類改訂第4版（2017）におけるリンパ系腫瘍

    II．赤血球系疾患
    　1．骨髄不全症の分子病態研究の進歩
    　2．加齢とクローン性造血
    　3．重症再生不良性貧血の治療
    　4．低リスクMDSの治療
    　5．高リスクMDSの治療
    　6．アザシチジン不応MDSの治療戦略
    　7．MDSに対する新規治療薬開発の現状
    　8．MDSに対する同種造血幹細胞移植
    　9．発作性夜間ヘモグロビン尿症の治療
    　10．腎性貧血

    III．白血病
    　A．急性骨髄性白血病（AML）
    　B．急性前骨髄球性白血病（APL）
    　C．急性リンパ性白血病（ALL）
    　D．慢性骨髄性白血病（CML）
    　E．骨髄増殖性腫瘍（MPN）

    IV．リンパ系腫瘍
    　A．慢性リンパ性白血病（CLL）
    　B．Indolent B細胞リンパ腫
    　C．マントル細胞リンパ腫
    　D．Aggressive B細胞リンパ腫
    　E．T／NK細胞リンパ腫
    　F．成人T細胞白血病／リンパ腫（ATLL）
    　G．ホジキンリンパ腫

    V．多発性骨髄腫と関連疾患
    　1．くすぶり型多発性骨髄腫に対する治療
    　2．移植適応初発多発性骨髄腫の治療
    　3．移植非適応初発多発性骨髄腫の治療
    　4．再発・難治多発性骨髄腫に対する治療
    　5．多発性骨髄腫に対する地固め・維持療法の意義
    　6．多発性骨髄腫に対する合併症の治療（腎，骨，感染症）
    　7．形質細胞性白血病の治療
    　8．原発性マクログロブリン血症の治療
    　9．原発性アミロイドーシスの治療
    　10．キャッスルマン病の治療
    　11．POEMS症候群の治療
    　12．TAFRO症候群の診断と治療

    VI．出血・血栓性疾患
    　1．難治性ITPの治療
    　2．血栓性血小板減少性紫斑病（TTP）の治療
    　3．aHUSの診断と治療
    　4．血友病治療の進歩
    　5．後天性血友病の診断と治療
    　6．DICの診断・治療

    VII．支持療法・輸血
    　1．造血器疾患患者の赤血球輸血における適切な目標ヘモグロビン値
    　2．造血器疾患患者の血小板輸血における適切な目標血小板数
    　3．輸血後鉄過剰症に対する介入によって得られる効果
    　4．ムーコル症の早期診断と治療
    　5．トキソプラズマ症の早期診断と治療
    　6．発熱性好中球減少症における適切な血液培養
    　7．造血器腫瘍患者における耐性菌
    　8．腫瘍崩壊症候群のマネージメント
    　9．血球貪食症候群の治療

    VIII．造血幹細胞移植
    　1．65歳以上の患者に対する同種造血幹細胞移植
    　2．同種造血幹細胞移植前後の免疫チェックポイント阻害薬使用の影響
    　3．同種造血幹細胞移植後の長期予後の評価指標
    　4．腸内細菌が同種移植後の経過に及ぼす影響
    　5．ステロイド抵抗性急性GVHDに対する救援治療
    　6．慢性GVHDに対する初期治療・救援療法
    　7．非寛解期急性白血病に対する同種造血幹細胞移植
    　8．同種造血幹細胞移植後のGVHDの発症と長期予後との関連
    　9．同種造血幹細胞移植後のサイトメガロウイルス感染症の管理

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I. 造血器腫瘍の新しい分類

P.8 掲載の参考文献
1) Jaffe ES, Harris NL, Stein H, et al (Editors). World Health Organization classification of tumours : pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press ; 2001.
 
2) Swerdlow SH, Campo E, Harris NL, et al (Editors). WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon : IARC Press ; 2008.
 
3) Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 127 : 2391-405.
 
4) Swerdlow SH, Campo E, Harris NL, et al (Editors). WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition, Lyon : IARC Press ; 2017.
 
P.14 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. World Health Organization Classification of Tumors : Tumors of haematopoietic and lymphoid tissues. Lyon France : IARC Press ; 2017.
 
2) 直江知樹, 朝長万左男, 中村栄男, 他, 編. WHO血液腫瘍分類-WHO分類 2008 をうまく活用するために-. 東京 : 医薬ジャーナル社, 2010年2月発行
 

II. 赤血球系疾患

P.21 掲載の参考文献
1) Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood. 2011 ; 118 : 6601-9.
PubMed
2) Afable MG, 2nd, Wlodarski M, Makishima H, et al. SNP array-based karyotyping : differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011 ; 117 : 6876-84.
PubMed
3) Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. N Engl J Med. 2015 ; 373 : 35-47.
PubMed
4) Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele closely involved in the autoantigen presentation in acquired aplastic anemia. Blood. 2017 ; 129 : 2908-16.
 
5) Imi T, Katagiri T, Hosomichi K, et al. Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia. Blood Adv. 2018 ; 2 : 1000-12.
PubMed
6) Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993 ; 73 : 703-11.
PubMed
7) Inoue N, Izui-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006 ; 108 : 4232-6.
PubMed
8) Krawitz PM, Hochsmann B, Murakami Y, et al. A case of paroxysmal nocturnal hemoglobinuria caused by a germline mutation and a somatic mutation in PIGT. Blood. 2013 ; 122 : 1312-5.
 
9) Shen W, Clemente MJ, Hosono N, et al. Deep sequencing reveals stepwise mutation acquisition in paroxysmal nocturnal hemoglobinuria. J Clin Invest. 2014 ; 124 : 4529-38.
PubMed
10) Clemente MJ, Przychodzen B, Hirsch CM, et al. Clonal PIGA mosaicism and dynamics in paroxysmal nocturnal hemoglobinuria. Leukemia. 2018. Epub ahead of print.
 
11) Mortazavi Y, Tooze JA, Gordon-Smith EC, et al. RAS gene mutation in patients with aplastic anemia and aplastic anemia/paroxysmal nocturnal hemoglobinuria during evolution to clonal disease. Blood. 2000 ; 95 : 646-50.
PubMed
12) Nakashima M, Kashii H, Murakami Y, et al. Novel compound heterozygous PIGT mutations caused multiple congenital anomalies-hypotonia-seizures syndrome 3. Neurogenetics. 2014 ; 15 : 193-200.
PubMed
13) Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 ; 370 : 632-9.
PubMed
14) Sanada M, Suzuki T, Shih LY, et al. Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms. Nature. 2009 ; 460 : 904-8.
PubMed
15) Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011 ; 478 : 64-9.
PubMed
16) Haferlach T, Nagata Y, Grossmann V, et al. Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia. 2014 ; 28 : 241-7.
PubMed
17) Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015 ; 27 : 658-70.
PubMed
18) Makishima H, Yoshizato T, Yoshida K, et al. Dynamics of clonal evolution in myelodysplastic syndromes. Nat Genet. 2017 ; 49 : 204-12.
PubMed
19) Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009 ; 360 : 2289-301.
PubMed
20) Jankowska AM, Szpurka H, Tiu RV, et al. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood. 2009 ; 113 : 6403-10.
PubMed
21) Ernst T, Chase AJ, Score J, et al. Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet. 2010 ; 42 : 722-6.
PubMed
22) Makishima H, Jankowska AM, Tiu RV, et al. Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies. Leukemia. 2010 ; 24 : 1799-804.
PubMed
23) Papaemmanuil E, Gerstung M, Malcovati L, et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood. 2013 ; 122 : 3616-27.
PubMed
24) Makishima H, Yoshida K, Nguyen N, et al. Somatic SETBP1 mutations in myeloid malignancies. Nat Genet. 2013 ; 45 : 942-6.
PubMed
P.26 掲載の参考文献
1) Busque L, Mio R, Mattioli J, et al. Nonrandom X-inactivation patterns in normal females : lyonization ratios vary with age. Blood. 1996 ; 88 : 59-65.
PubMed
2) Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 ; 371 : 2488-98.
PubMed
3) Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014 ; 371 : 2477-87.
PubMed
4) Malcovati L, Galli A, Travaglino E, et al. Clinical significance of somatic mutation in unexplained blood cytopenia. Blood. 2017 ; 129 : 3371-8.
PubMed
5) Gibson CJ, Lindsley RC, Tchekmedyian V, et al. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. J Clin Oncol 2017 ; 35 : 1598-605.
PubMed
6) Jaiswal S, Natarajan P, Silver AJ, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. N Engl J Med. 2017 ; 377 : 111-21.
PubMed
7) Gibson CJ, Kennedy JA, Nikiforow S, et al. Donor-engrafted CHIP is common among stem cell transplant recipients with unexplained cytopenias. Blood. 2017 ; 130 : 91-4.
PubMed
8) Gondek LP, Zheng G, Ghiaur G, et al. Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia. 2016 ; 30 : 1916-20.
PubMed
9) Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015 ; 126 : 9-16.
PubMed
10) Young AL, Challen GA, Birmann BM, et al. Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults. Nat Commun. 2016 ; 7 : 12484.
PubMed
P.32 掲載の参考文献
1) Scheinberg P, Nunez O, Weinstein B, et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med. 2011 ; 365 : 430-8.
PubMed
2) Marsh JC, Bacigalupo A, Schrezenmeier H, et al. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party. Blood. 2012 ; 119 : 5391-6.
PubMed
3) Takahashi Y, Muramatsu H, Sakata N, et al. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia. Blood. 2013 ; 121 : 862-3.
PubMed
4) Jeong DC, Chung NG, Cho B, et al. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica. 2014 ; 99 : 664-71.
PubMed
5) Frickhofen N, Heimpel H, Kaltwasser JP, et al. Antithymocyte globulin with or without cyclosporin A : 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003 ; 101 : 1236-42.
 
6) 再生不良性貧血の診断基準と診療の参照ガイド作成のためのワーキンググループ. 再生不良性貧血診療の参照ガイド 2018年改訂 (http://zoketsushogaihan.com/file/guideline_H30/02.pdf). Accessed 2018 June 16.
 
7) Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia : Outcome of 955 patients treated 2001-2012. Am J Hematol. 2018 ; 93 : 643-8.
PubMed
8) Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 ; 376 : 1540-50.
PubMed
9) Park SS, Kwak DH, Jeon YW, et al. Beneficial role of low-dose antithymocyte globulin in unrelated stem cell transplantation for adult patients with acquired severe aplastic anemia : reduction of graft-versus-host disease and improvement of graft-versus-host disease-free, failure-free survival rate. Biol Blood Marrow Transplant. 2017 ; 23 : 1498-508.
PubMed
10) Anderlini P, Wu J, Gersten I, et al. Cyclophosphamide conditioning in patients with severe aplastic anaemia given unrelated marrow transplantation : a phase 1-2 dose de-escalation study. Lancet Haematol. 2015 ; 2 : e367-75.
PubMed
11) Shin SH, Jeon YW, Yoon JH, et al. Comparable outcomes between younger (> 40 years) and older (> 40 years) adult patients with severe aplastic anemia after HLA-matched sibling stem cell transplantation using fludarabine-based conditioning. Bone Marrow Transplant. 2016 ; 51 : 1456-63.
PubMed
P.38 掲載の参考文献
1) Greenberg P, Cox C, LeBeau MM, et al. International coring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 ; 89 : 2079-88.
 
2) Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 ; 120 : 2454-65.
PubMed
3) Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011 ; 364 : 2496-506.
PubMed
4) Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodyasplastic syndromes. J Clin Oncol. 2012 ; 30 : 3376-82.
PubMed
5) Kawabata H, Tohyama K, Matsuda A, et al. Validation of the revised international prognostic scoring system in patients with myelodysplastic syndromes in Japan : results from a prospective multicenter registry. Int J Hematol. 2017 ; 106 : 375-84.
PubMed
6) Komrokji RS, List AF. Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del (5q) MDS. Ann Oncol. 2016 ; 27 : 62-8.
 
7) Della Porta MG, Jackson CH, Alessandrino EP, et al. Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognosis Scoring System. Leukemia. 2017 ; 31 : 2449-57.
 
8) 日本血液学会, 編集. 骨髄異形成症候群. In : 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018. 144-59.
 
9) Nakao S, Gale RP. Are mild/moderate acquired idiopathic aplastic anaemia and low-risk myelodysplastic syndrome one or two diseases or both and how should it/they treated? Leukemia. 2016 ; 30 : 2127-30.
 
10) Stahl M, De Veaux M, de Witte T, et al. The use of immunesuppresive therapy in MDS : clinical outcomes and their predictors in large international cohort. Blood Adv. 2018 ; 2 : 1765-72.
PubMed
11) Platzbecker U, Symeonidis A, Oliva EN, et al. A phase 3 randomized placebo-controlled trial of darbepoetin alpha in patients with anemia and lower-risk myelodysplastic syndromes. Leukemia. 2017. 31 : 1944-50.
 
12) Santini V. Anemia as the main manifestation of myelodysplastic syndromes. Semin Hematol. 2015 ; 52 : 348-56.
PubMed
13) Pileggi C, Di Sanzo M, Mascaro V, et al. Role of serum ferritin level on overall survival in patients with myelodysplastic syndromes : Results of a meta-analysis of observational studies. PLoS One. 2017 ; 12 : e0179016.
PubMed
14) Leitch HA, Parmar A, Wells RA, et al. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy adjusting for patients-related factors and measuring from time of first red blood cell transfusion dependence : an MDS-CAN analysis. Br J Haematol. 2017 ; 179 : 83-97.
PubMed
15) Rose C, Lenoir C, Gyan E, et al. Prospective evaluation of the effect of deferasirox on hematologic response in transfusion-dependent patients with low risk MDS and iron overload. Eur J Haematol. 2018 Epub ahead of print.
 
16) Fill C, Malagola M, Follo MY, et al. Prospective phase II study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes. Clin Cancer Res. 2013 ; 19 : 3297-308.
 
17) 再生不良性貧血の診断基準と診療の参照ガイド作成のためのワーキンググループ. 再生不良性貧血の参照ガイド 2018年改訂 http://zoketsushogaihan.com/file/guideline_H30/02.pdf
 
P.45 掲載の参考文献
1) Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 ; 89 : 2079-88.
PubMed
2) Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 ; 120 : 2454-65.
PubMed
3) Greenberg PL, Stone RM, Al-Kali A, et al. NCCN Clinical Practice Guidelines in Oncology, Myelodysplastic Syndromes, Version 2.2017. J Nat Compr Canc Netw. 2017 ; 15 : 60-87.
 
4) 宮崎泰司, 市川 幹, 鈴木隆浩, 他. 骨髄異形成症候群 (MDS). In : 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018. p. 144-64.
 
5) Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes : delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 ; 104 : 579-85.
 
6) Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes : an international collaborative decision analysis. J Clin Oncol. 2013 ; 31 : 2662-70.
PubMed
7) Della Porta MG, Malcovati L, Strupp C, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica. 2011 ; 90 : 441-9.
 
8) Shaffer BC, Ahn KW, Hu ZH, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016 ; 34 : 1864-71.
PubMed
9) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. International Vidaza High-Risk MDS Survival Study Group. Efficacy ofzacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol. 2009 ; 10 : 223-32.
 
10) Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (> 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010 ; 76 : 218-27.
PubMed
11) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010 ; 28 : 562-9.
PubMed
12) Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 ; 98 : 1067-72.
PubMed
13) Seymour JF, Bennett JM, List AF, et al. Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes. Br J Haematol. 2014 ; 165 : 49-56.
PubMed
14) Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes : a study by the societe francaise de greffe de moelle et de therapie-cellulaire and the groupe-francophone des myelodysplasies. J Clin Oncol. 2012 ; 34 : 4533-40.
 
15) Miller KB, Kim K, Morrison FS, et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes : a phase-III intergroup study. Ann Hematol. 1992 ; 65 : 162-8.
PubMed
16) Morita Y, Kanamaru A, Miyazaki Y, et al. Comparative analysis of remission induction therapy for high-risk MDS and AML progressed from MDS in the MDS200 study of Japan Adult Leukemia Study Group. Int J Hematol. 2010 ; 91 : 97-103.
 
17) Robin M, Porcher R, Ades L, et al. HLA-matched allogeneic stem cell transplantation improves outcome of higher risk myelodysplastic syndrome A prospective study on behalf of SFGM-TC and GFM. Leukemia. 2015 ; 29 : 1496-501.
 
18) Lindsley RC, Saber W, Mar BG, et al. Prognostic Mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017 ; 376 : 536-47.
PubMed
19) Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 ; 375 : 2023-36.
PubMed
20) Prebet T, Gore SD, Estemi B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011 ; 29 : 3322-7.
 
21) Sekeres MA, Othus M, List AF, et al. Randomized phase IIstudy of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia : north american intergroup study SWOG S1117. J Clin Oncol. 2017 ; 35 : 2745-53.
 
22) Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014 ; 124 : 2705-12.
PubMed
P.52 掲載の参考文献
1) Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes : a randomised, open-label, phase III study. Lancet Oncol. 2009 ; 10 : 223-32.
PubMed
2) Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011 ; 117 : 403-11.
PubMed
3) Prebet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin oncol. 2011 ; 29 : 3322-7.
PubMed
4) Jabbour EJ, Garcia-Manero G, Strati P, et al. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure : a report on behalf of the MDS Clinical Research Consortium. Cancer. 2015 ; 121 : 876-82.
 
5) Fenaux P, Bowen D, Gattermann N, et al. Practical use of azacitidine in higher-risk myelodysplastic syndromes : an expert panel opinion. Leukemia Research. 2010 ; 34 : 1410-6.
 
6) Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine*. Eur J Haematol. 2010 ; 85 : 130-8.
PubMed
7) Gore SD, Fenaux P, Santini V, et al. A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial. Haematologica. 2013 ; 98 : 1067-72.
PubMed
8) Montalban-Bravo G, Garcia-Manero G, Jabbour E. Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes. Curr Opin Hematol. 2018 ; 25 : 146-53.
PubMed
9) Festuccia M, Baker K, Gooley TA, et al. Hematopoietic Cell Transplantation in Myelodysplastic Syndromes after Treatment with Hypomethylating Agents. Biol Blood Marrow Transplant. 2017 ; 23 : 1509-14.
PubMed
10) Yoshizato T, Nannya Y, Atsuta Y, et al. Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia : impact on outcome of stem cell transplantation. Blood. 2017 ; 129 : 2347-58.
PubMed
11) Prebet T, Charbonnier A, Gelsi-Boyer V, et al. Lenalidomide treatment for patients with myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Leukemia & lymphoma. 2013 ; 54 : 1538-40.
PubMed
12) Jabbour E, Faderl S, Sasaki K, et al. Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents. Cancer. 2017 ; 123 : 629-37.
PubMed
13) Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME) : a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 ; 17 : 496-508.
PubMed
14) Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 ; 375 : 2023-36.
PubMed
15) DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. Am J hematol 2018 ; 93 : 401-7.
PubMed
P.57 掲載の参考文献
1) Platzbecker U, Germing U, Gotze KS, et al. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS) : a multicentre, open-label phase 2 dose-finding study with long-term extension study. Lancet Oncol. 2017 ; 18 : 1338-47.
PubMed
2) Kantarjian HM, Fenaux P, Sekeres MA, et al. Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial. Lancet Haematol. 2018 ; 5 : e117-e26.
PubMed
3) Issa JJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia : a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 2015 ; 16 : 1099-110.
PubMed
4) Garcia-Manero G, Fenaux P, Al-Kali A, et al. Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME) : a randomised, controlled, phase 3 trial. Lancet Oncol. 2016 ; 17 : 496-508.
PubMed
5) Ueda Y, Ogura M, Miyakoshi S, et al. Phase 1/2 study of the WT1 peptide cancer vaccine WT4869 in patients with myelodysplastic syndrome. Cancer Sci. 2017 ; 108 : 2445-53.
PubMed
6) Oliva EN, Alati C, Santini V, et al. Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS) : phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial. Lancet Haematol. 2017 ; 4 : e127-e36.
PubMed
7) Olnes MJ, Scheinberg P, Calvo KR, et al. Eltrombopag and improved hematopoiesis in refractory aplastic anemia. N Engl J Med. 2012 ; 367 : 11-9.
PubMed
8) Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia. N Engl J Med. 2017 ; 376 : 1540-50.
PubMed
9) Navada SC, Fruchtman SM, Odchimar-Reissig R, et al. A phase 1/2 study of rigosertib in patients with myelodysplastic syndromes (MDS) and MDS progressed to acute myeloid leukemia. Leuk Res. 2018 ; 64 : 10-6.
PubMed
P.62 掲載の参考文献
1) Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997 ; 89 : 2079-88.
PubMed
2) Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 ; 120 : 2454-65.
PubMed
3) Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes : delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood. 2004 ; 104 : 579-85.
 
4) Koreth J, Pidala J, Perez WS, et al. Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes : an international collaborative decision analysis. J Clin Oncol. 2013 ; 31 : 2662-70.
PubMed
5) Muffly LS, Kocherginsky M, Stock W, et al. Geriatric assessment to predict survival in older allogeneic hematopoietic cell transplantation recipients. Haematologica. 2014 ; 99 : 1373-9.
PubMed
6) Itzykson R, Thepot S, Quesnel B, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011 ; 117 : 403-11.
PubMed
7) Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002 ; 100 : 1997-2004.
PubMed
8) Platzbecker U, Mufti G. Allogeneic stem cell transplantation in MDS : How? When? Best Pract Res Clin Haematol. 2013 ; 26 : 421-9.
PubMed
9) Damaj G, Duhamel A, Robin M, et al. Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes : a study by the societe francaise de greffe de moelle et de therapie-cellulaire and the groupe-francophone des myelodysplasies. J Clin Oncol. 2012 ; 30 : 4533-40.
PubMed
10) Kawamura K, Kako S, Mizuta S, et al. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 Years or older. Biol Blood Marrow Transplant. 2017 ; 23 : 2079-87.
PubMed
11) Shaffer BC, Ahn KW, Hu ZH, et al. Scoring system prognostic of outcome in patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome. J Clin Oncol. 2016 ; 34 : 1864-71.
PubMed
12) Della Porta MG, Alessandrino EP, Bacigalupo A, et al. Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood. 2014 ; 123 : 2333-42.
 
13) Bejar R, Stevenson KE, Caughey B, et al. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol. 2014 ; 32 : 2691-8.
PubMed
14) Welch JS, Petti AA, Miller CA, et al. TP53 and decitabine in acute myeloid leukemia and myelodysplastic syndromes. N Engl J Med. 2016 ; 375 : 2023-36.
PubMed
15) Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017 ; 376 : 536-47.
PubMed
16) Bally C, Thepot S, Quesnel B, et al. Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML) : a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM). Leuk Res. 2013 ; 37 : 637-40.
PubMed
17) Scott BL, Pasquini MC, Logan BR, et al. Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes. J Clin Oncol. 2017 ; 35 : 1154-61.
PubMed
18) Kroger N, Iacobelli S, Franke GN, et al. Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome : A prospective randomized Phase III study of the EBMT (RICMAC Trial). J Clin Oncol. 2017 ; 35 : 2157-64.
 
P.68 掲載の参考文献
1) 川口辰哉. 発作性夜間ヘモグロビン尿症 (PNH) -最新の治療指針-. 臨床血液. 2018 ; 59 : 703-10.
 
2) Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria : sustained efficacy and improved survival. Blood. 2011 ; 117 : 6786-92.
PubMed
3) Nishimura J, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014 ; 370 : 632-9.
PubMed
4) アレクシオンファーマ. ソリリス点滴静注300 mg 特定使用成績調査 発作性夜間ヘモグロビン尿症 (PNH) 安全性定期報告概要 2017年度版. 2017.
 
5) 厚生労働科学研究費補助金難治性疾患克服研究事業 特発性造血障害に関する調査研究班. 発作性夜間ヘモグロビン尿症診療の参照ガイド. 平成28年度改訂版 (研究代表者 荒井俊也). (http://zoketsushogaihan.com/file/guideline_H28/05.pdf) Accessed 2018 July 26.
 
6) Ninomiya H, Obara N, Chiba S, et al. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan. Int J Hematol. 2016 ; 104 : 548-58.
PubMed
7) Peffault de Latour R, Fremeaux-Bacchi V, Porcher R et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015 ; 29 : 775-83.
 
8) McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. Morb Mortal Wkly Rep. 2017 ; 66 : 734-7.
PubMed
P.74 掲載の参考文献
1) Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol Chem. 1977 ; 225 : 5558-64.
 
2) Kalantar-Zadeh K. History of erythropoiesis-stimulating agents, the development of biosimilars, and the future of anemia treatment in nephrology. Am J Nephrol. 2017 ; 45, 235-47.
PubMed
3) Obara N, Suzuki N, Kim K, et al. Repression via the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 2008 ; 111 : 5223-32.
PubMed
4) Suzuki N, Obara N, Pan X, et al. Specific contribution of the erythropoietin gene 3'enhancer to hepatic erythropoiesis after late embryonic stages. Mol Cell Biol. 2011 ; 31 : 3896-905.
PubMed
5) Asada N, Takase M, Nakamura J, et al. Dysfunction of fibroblasts of extrarenal origin underlies renal fibrosis and renal anemia in mice. J Clin Invest 2011 ; 121 : 3981-3990.
PubMed
6) Pan X, Suzuki N, Hirano I, et al. Isolation and characterization of renal erythropoietin-producing cells from genetically produced anemia mice. PLoS One. 2011 ; 6 : e25839.
PubMed
7) Nangaku M, Rosenberger C, Heyman SN, et al. Regulation of hypoxia-inducible factor in kidney disease. Clin Exp Pharmacol Physiol. 2013 ; 40 : 148-57.
PubMed
8) Morita N, Ohneda O, Yamashita T, et al. HLF/HIF-2α is a key factor in retinopathy of prematurity in association with erythropoietin. EMBO. 2003 ; 22 : 1134-46.
 
9) 日本透析医学会 慢性腎臓病患者における腎性貧血治療のガイドライン改訂ワーキンググループ. 2015年版 日本透析医学会. 慢性腎臓病患者における腎性貧血治療のガイドライン. 透析会誌. 2016 ; 49 : 89-158.
 
10) 椿原美治. 腎性貧血を呈する保存期慢性腎不全患者の血漿EPO濃度の解析. 日腎会誌. 2007 ; 49 : 292.
 
11) Akizawa T, Saito A, Geiyo E, et al. Low hemoglobin levels and hypo-responsiveness to erythropoiesis-stimulating agent associated with poor survival in incident Japanese hemodialysis patients. Ther Apher Dial. 2014 ; 18 : 404-13.
 
12) Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 2009 ; 361 : 2019-32.
 
13) Imai E, Yamamoto R, Suzuki H et al. Incidence of symptomatic stroke and cancer in chronic kidney disease patients treated with epoetins. Clin Exp Nephrol. 2010 ; 14 : 445-52.
PubMed
14) Stancu S, Stanciu A, Zugravu A, et al. Bone marrow iron, iron indices, and the response to intravenous iron in patients with non-dialysis-dependent CKD. Am J Kidney Dis. 2010 ; 55 : 639-47.
PubMed
15) Hamano T, Fujii N, Hayashi T, et al. Thresholds of iron markers for iron deficiency erythropoiesis-finding of the Japanese nationwide dialysis registry. Kidney Int Suppl (2011). 2015 ; 5 : 23-32.
PubMed
16) KDOQI. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease : 2007 update of hemoglobin target. Am J Kidney Dis. 2007 ; 50 : 471-530.
PubMed
17) Provenzano R, Besarab A, Sun CH, et al. Oral Hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD. Clin J Am Soc Nephrol. 2016 ; 11 : 982-91.
PubMed
18) Provenzano R, Besarab A, Wright S, et al. Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis : A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis. 2016 ; 67 : 912-24.
 

III. 白血病

P.79 掲載の参考文献
1) Bullinger L, Dohner K, Dohner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017 ; 35 : 934-46.
PubMed
2) Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues : Revised 4th Edition, Lyon : IARC ; 2017.
 
3) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
4) Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016 ; 374 : 2209-21.
PubMed
5) Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013 ; 121 : 2213-23.
PubMed
6) Paschka P, Du J, Schlenk RF, Gaidzik VI, et al. Secondary genetic lesions in acute myeloid leukemia with inv (16) or t (16 ; 16) : a study of the German-Austrian AML Study Group (AMLSG). Blood. 2013 ; 121 : 170-7.
PubMed
7) Harada Y, Nagata Y, Kihara R, et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res. 2018 ; 66 : 20-7.
 
P.84 掲載の参考文献
1) Rai KR, Holland JF, Glidewell OJ, et al. Treatment of acute myelocytic leukemia : a study by cancer and leukemia group B. Blood. 1981 ; 58 : 1203-12.
 
2) Berman E, Heller G, Santorsa J, et al. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood. 1991 ; 77 : 1666-74.
PubMed
3) Wiernik PH, Banks PL, Case DC, Jr, et al. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Blood. 1992 ; 79 : 313-9.
PubMed
4) Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009 ; 361 : 1249-59.
PubMed
5) Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009 ; 361 : 1235-48.
PubMed
6) Luskin MR, Lee JW, Fernandez HF, et al. Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016 ; 127 : 1551-8.
PubMed
7) Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998 ; 58 : 4173-9.
PubMed
8) Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission : systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 ; 301 : 2349-61.
PubMed
9) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
10) O'Donnell M, Tallman MS, Abboud CN, et al. NCCN clinical practice guidelines in oncology, acute myeloid leukemia, version 1. 2018. 2018 : https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf.
 
11) Ohtake S, Miyawaki S, Fujita H, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia : the JALSG AML201 Study. Blood. 2011 ; 117 : 2358-65.
PubMed
12) 日本血液学会. 造血器腫瘍ガイドライン 2018年版. 東京 : 金原出版 ; 2018 : . p.8-37.
 
13) Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood. 2011 ; 117 : 2366-72.
PubMed
14) Lee JH, Kim H, Joo YD, et al. Prospective randomized comparison of idarubicin and high-dose daunorubicin in induction chemotherapy for newly diagnosed acute myeloid leukemia. J Clin Oncol. 2017 ; 35 : 2754-63.
 
15) Burnett AK, Russell NH, Hills RK, et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2 in AML induction : results from the UK NCRI AML17 trial in 1206 patients. Blood. 2015 ; 125 : 3878-85.
PubMed
16) Burnett AK, Russell NH, Hills RK, United Kingdom National Cancer Research Institute Acute Myeloid Leukemia Study G. Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia. Blood. 2016 ; 128 : 449-52.
 
17) Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701) : a randomised, open-label, phase 3 study. Lancet. 2012 ; 379 : 1508-16.
PubMed
18) Magina KN, Pregartner G, Zebisch A, et al. Cytarabine dose in the consolidation treatment of AML : a systematic review and meta-analysis. Blood. 2017 ; 130 : 946-8.
PubMed
19) Lowenberg B, Pabst T, Vellenga E, et al. Cytarabine dose for acute myeloid leukemia. N Engl J Med. 2011 ; 364 : 1027-36.
PubMed
20) Schaich M, Rollig C, Soucek S, et al. Cytarabine dose of 36 g/m2 compared with 12 g/m2 within first consolidation in acute myeloid leukemia : results of patients enrolled onto the prospective randomized AML96 study. J Clin Oncol. 2011 ; 29 : 2696-702.
PubMed
21) Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with acute myeloid leukemia : results of the medical research council AML15 trial. J Clin Oncol. 2013 ; 31 : 3360-8.
 
22) Lowenberg B. Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. Blood. 2013 ; 121 : 26-8.
PubMed
23) Wu D, Duan C, Chen L, et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients : a network meta-analysis. Sci Rep. 2017 ; 7 : 9509.
PubMed
24) Kern W, Estey EH. High-dose cytosine arabinoside in the treatment of acute myeloid leukemia : Review of three randomized trials. Cancer. 2006 ; 107 : 116-24.
PubMed
P.92 掲載の参考文献
1) Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006 ; 107 : 3481-5.
PubMed
2) Deschler B, Ihorst G, Platzbecker U, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013 ; 98 : 208-16.
PubMed
3) Rao AV. Fitness in the elderly : how to make decisions regarding acute myeloid leukemia induction. Hematology Am Soc Hematol Educ Program. 2016 ; 2016 : 339.
PubMed
4) Ostgard LS, Norgaard JM, Sengelov H, et al. Comorbidity and performance status in acute myeloid leukemia patients : a nation-wide population-based cohort study. Leukemia. 2015 ; 29 : 548-55.
PubMed
5) Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018 ; 131 : 515-24
 
6) Mikkael A. Sekeres, Elson P, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009 ; 113 : 28-36.
 
7) Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with > 30% blasts. Blood. 2015 ; 126 : 291-9.
PubMed
8) Juliusson G, Antunovic P, Derolf P, et al. Age and acute myeloid leukemia : real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009 ; 113 : 4179-87.
 
9) Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013 ; 121 : 4287-94.
PubMed
10) Burnett AK, Milligan D, Prentice AG, et al. A Comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007 ; 109 : 1114-24.
 
11) Minakata D, Fujiwara S, Ito S, et al. A low-dose cytarabine, aclarubicin and granulocyte colony-stimulating factor priming regimen versus a daunorubicin plus cytarabine regimen as induction therapy for older patients with acute myeloid leukemia : A propensity score analysis. Leuk Res. 2016 ; 42 : 82-7.
PubMed
12) Aoki J, Kanamori H, Tanaka M, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016 ; 91 : 302-7.
PubMed
13) Kanemura N, Tsurumi H, Kasahara S, et al. Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony-stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematol Oncol. 2008 ; 26 : 33-8.
PubMed
14) Shin SH, Cho BS, Park SS, et al. Comparison of the modified low-dose cytarabine and etoposide with decitabine therapy for elderly acute myeloid leukemia patients unfit for intensive chemotherapy. Oncotarget. 2018 ; 9 : 5823-33.
PubMed
15) Mayer RJ, Davis RB, Schiffer CA, et al. Cancer and Leukemia Group B. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994 ; 331 : 896- 903.
 
16) Goldstone AH, Burnett AK, Wheatley K, et al. Medical Research Council Adult Leukemia Working Party. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older pa- tients : the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001 ; 98 : 1302-11.
 
17) Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant. 2011 ; 17 : 1796-803.
PubMed
18) DiNardo CD, Pratz KW, Letai A, et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia : a non-randomised, open-label, phase 1b study. Lancet Oncol. 2018 ; 19 : 216-28.
PubMed
P.98 掲載の参考文献
1) Breems DA, Van Putten WL, Huijgens PC, et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005 ; 23 : 1969-78.
PubMed
2) Kurosawa S, Yamaguchi T, Miyawaki S, et al. Prognostic factors and outcomes of adult patients with acute myeloid leukemia after first relapse. Haematologica. 2010 ; 95 : 1857-64.
PubMed
3) Chevallier P, Labopin M, Turlure P, et al. A new leukemia prognostic scoring system for refractory/relapsed adult acute myelogeneous leukaemia patients : a GOELAMS study. Leukemia. 2011 ; 25 : 939-44.
PubMed
4) Wei G, Ni W, Chiao JW, et al. A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome. J Hematol Oncol. 2011 ; 4 : 46.
PubMed
5) Schlenk RF, Frech P, Weber D, et al. Impact of pretreatment characteristics and salvage strategy on outcome in patients with relapsed acute myeloid leukemia. Leukemia. 2017 ; 31 : 1217-20.
PubMed
6) Wattad M, Weber D, Dohner K, et al. Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure. Leukemia. 2017 ; 31 : 1306-13.
PubMed
7) Weisdorf DJ, Millard HR, Horowitz MM, et al. Allogeneic transplantation for advanced acute myeloid leukemia : The value of complete remission. Cancer. 2017 ; 123 : 2025-34.
PubMed
8) Stahl M, DeVeaux M, Montesinos P, et al. Hypomethylating agents in relapsed and refractory AML : outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 ; 2 : 923-32.
 
P.103 掲載の参考文献
1) Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults : 2017 ELN recommendations from an international expert panel. Blood. 2017 ; 129 : 424-47.
 
2) Miyawaki S, Ohtake S, Fujisawa S, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults : the JALSG AML201 Study. Blood. 2011 ; 117 : 2366-72.
PubMed
3) Kuwatsuka Y, Miyamura K, Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia : t (8 ; 21) and inv (16) represent different clinical outcomes. Blood. 2009 ; 113 : 2096-103.
PubMed
4) Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse : results of the United Kingdom MRC AML-15 trilal. Blood. 2012 ; 120 : 2826-35.
PubMed
5) Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013 ; 121 : 2213-23.
PubMed
6) Schuurhuis GJ, Heuser M, Freeman S, et al. Minimal/measurableresidual disease in AML : a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018 ; 131 : 1275-91.
 
P.108 掲載の参考文献
1) Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission : systematic review and meta-analysis of prospective clinical trials. JAMA. 2009 ; 301 : 2349-61.
PubMed
2) https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf
 
3) Ostgard LSG, et al. Impact of allogeneic stem cell transplantation in first complete remission in acute myeloid leukemia : A National Population-Based Cohort Study. Biol Blood Marrow Transplant. 2018 ; 24 : 314-323.
PubMed
4) Bornhauser M, Kienast J, Trenschel R, et al. Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission : a prospective, open-label randomised phase 3 trial. Lancet Oncol. 2012 ; 13 : 1035-44.
PubMed
5) Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Advances. 2017 ; 1 : 477-85.
PubMed
6) Aoki J, Kanamori H, Tanaka M, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016 ; 91 : 302-7.
PubMed
7) Wang ES. Treating acute myeloid leukemia in older adults. Hematology Am Soc Hematol Educ Program. 2014 : 14-20.
PubMed
8) Kawamura K, Kako S, Mizuta S, et al. Comparison of conditioning with fludarabine/busulfan and fludarabine/melphalan in allogeneic transplantation recipients 50 years or older. Biol Blood Marrow Tranplant. 2017 ; 23 : 2079-87.
PubMed
P.112 掲載の参考文献
1) Dohner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med. 2015 ; 373 : 1136-52.
PubMed
2) Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017 ; 377 : 454-64.
PubMed
3) Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017 ; 130 : 722-31.
 
4) Lancet JE, Uy GL, Cortes JE, et al. CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia. J Clin Oncol. 2018 (in press)
 
5) Hills RK, Castaigne S, Appelbaum FR, et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia : a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 2014 ; 15 : 986-96.
PubMed
6) Wei A, Strickland SA, Roboz GJ, et al. Safety and efficacy of venetoclax plus low-dose cytarabine in treatment-naive patients aged > = 65 years with acute myeloid leukemia. Blood. 2016 ; 128 : 102.
 
7) Perl AE. The role of targeted therapy in the management of patients with AML. Blood Adv. 2017 ; 1 : 2281-94.
PubMed
8) Wei AH, Tiong IS. Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML. Blood. 2017 ; 130 : 2469-74.
 
P.117 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of tumours of haematopoietic & lymphoid tissues, 4th ed., Revised ed. Lyon : IARC Press ; 2017.
 
2) Godley LA, Shimamura A. Genetic predisposition to hematologic malignancies : management and surveillance. Blood. 2017 ; 130 : 424-32.
PubMed
3) Porter CC, Druley TE, Erez A, et al. Recommendations for surveillance for children with leukemia-predisposing conditions. Clin Cancer Res. 2017 ; 23 : e14-e22.
PubMed
4) Polprasert C, Schulze I, Sekeres MA, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015 ; 27 : 658-70.
PubMed
5) Wlodarski MW, Hirabayashi S, Pastor V, et al. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016 ; 127 : 1387-97.
PubMed
P.121 掲載の参考文献
1) Asou N, Fujita H, Shinagawa K. JSH guideline for tumors of hematopoietic and lymphoid tissues : leukemia : 2. Acute promyelocytic leukemia (APL). Int J Hematol. 2017 ; 106 : 459-70.
PubMed
2) Platzbecker U, Avvisati G, Cicconi L, et al. Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia : Final results of the randomized Italian-German APL0406 trial. J Clin Oncol. 2017 ; 35 : 605-12.
 
3) Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 ; 369 : 111-21.
PubMed
4) Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2017 ; 129 : 1275-83.
PubMed
5) Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17) : results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1295-305.
PubMed
6) Iland HJ, Collins M, Bradstock K, et al. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study : a non-randomised phase 2 trial. Lancet Haematol. 2015 ; 2 : e357-66.
PubMed
7) Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia : results from a randomized controlled trial. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
P.126 掲載の参考文献
1) Muchtar E, Vidal L, Ram R, et al. The role of maintenance therapy in acute promyelocytic leukemia in the first complete remission. Cochrane Database Syst Rev. 2013 : CD009594.
PubMed
2) Iland H, Bradstock K, Seymour J, et al. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica. 2012 ; 97 : 227-34.
PubMed
3) Shinagawa K, Yanada M, Sakura T, et al. Tamibarotene as maintenance therapy for acute promyelocytic leukemia : results from a randomized controlled trial. J Clin Oncol. 2014 ; 32 : 3729-35.
PubMed
4) Coutre SE, Othus M, Powell B, et al. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol. 2014 ; 165 : 497-503.
PubMed
5) Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 ; 120 : 1570-80.
PubMed
6) Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 ; 369 : 111-21.
PubMed
P.130 掲載の参考文献
1) Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high risk patients : further improvements in treatment outcomes. Blood. 2010 ; 115 : 5137-46.
PubMed
2) Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 ; 19 : 3852-60.
 
3) Raffoux E, Rousselot P, et al. Combined treatment with arsenic trioxide and all-trans retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol. 2003 ; 21 : 2326-34.
PubMed
4) Yamada M, Tsuzuki M, Fujita H, et al. Phase 2 study of arsenic trioxide followed by autologous hematopoietic cell transplantation for relapsed acute promyelocytic leukemia. Blood. 2013 ; 121 : 3095-102.
 
5) Lo-Coco F, Cimino G, Breccia M, et al. Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood. 2004 ; 104 : 1995-9.
PubMed
6) Tobita T, Takeshita A, Kitamura K, et al. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid. Blood. 1997 ; 90 : 967-73.
PubMed
7) Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 ; 369 : 111-21.
PubMed
8) Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17) : results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1295-305.
PubMed
P.135 掲載の参考文献
1) Jabbour E, Kantarjian HM, Saglio G, et al. Early response with dasatinib or imatinib in chronic myeloid leukemia : 3-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2014 ; 123 : 494-500.
 
2) Porkka K, Koskenvesa P, Lundan T, et al. Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia. Blood. 2008 ; 112 : 1005-12.
PubMed
3) Hatta Y, Mizuta S, Matsuo K, et al. Final analysis of the JALSG Ph+ALL202 study : tyrosine kinase inhibitor-combined chemotherapy for Ph+ALL. Ann Hematol. 2018. Epub ahead of print.
 
4) Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 ; 118 : 6521-8.
PubMed
5) Pfeifer H, Wassmann B, Bethge W, et al. Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia. Leukemia. 2013 ; 27 : 1254-62.
PubMed
6) Sasaki K, Jabbour EJ, Ravandi F, et al. Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia : A propensity score analysis. Cancer. 2016 ; 122 : 3650-6.
PubMed
7) Ravandi F, O'Brien SM, Cortes JE, et al. Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Cancer. 2015 ; 121 : 4158-64.
PubMed
8) Chalandon Y, Thomas X, Hayette S, et al. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia. Blood. 2015 ; 125 : 3711-9.
 
9) Tanguy-Schmidt A, Rousselot P, Chalandon Y, et al. Long-term follow-up of the imatinib GRAAPH-2003 study in newly diagnosed patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia : a GRAALL study. Biol Blood Marrow Transplant. 2013 ; 19 : 150-5.
 
10) Swerdlow SH, Campo E, Harris NL, et al (editors). WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th Edition, Lyon : IARC Press ; 2017.
 
11) Roberts KG, Morin RD, Zhang J, et al. Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell. 2012 ; 22 : 153-66.
PubMed
P.140 掲載の参考文献
1) Litzow MR. Evolving paradigms in the therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults. Hematology Am Soc Hematol Educ Program. 2009 ; 362-70.
PubMed
2) Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : the GRAALL-2003 study. J Clin Oncol. 2009 ; 27 : 911-8.
 
3) Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia : analysis of the LALA-94 trial. J Clin Oncol. 2004 ; 22 : 4075-86.
 
4) Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission : an individual patient data meta-analysis. Blood. 2013 ; 121 : 339-50.
PubMed
5) Kako S, Morita S, Sakamaki H, et al. A decision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia. 2011 ; 25 : 259-65.
PubMed
6) Takeuchi J, Kyo T, Naito K, et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia : the JALSG-ALL93 study. Leukemia. 2002 ; 16 : 1259-66.
PubMed
7) Jinnai I, Sakura T, Tsuzuki M, et al. Intensified consolidation therapy with dose-escalated doxorubicin did not improve the prognosis of adults with acute lymphoblastic leukemia : the JALSG-ALL97 study. Int J Hematol. 2010 ; 92 : 490-502.
 
8) Atsuta Y. Introduction of Transplant Registry Unified Management Program 2 (TRUMP2) : scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol. 2016 ; 103 : 3-10.
 
9) Hayakawa F, Sakura T, Yujiri T, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014 ; 4 : e252.
 
10) Sakura T, Hayakawa F, Sugiura I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia : a phase III study by JALSG. Leukemia. 2018 ; 32 : 626-32.
PubMed
11) Dhedin N, Huynh A, Maury S, et al. Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia. Blood. 2015 ; 125 : 2486-96 ; quiz 2586.
 
P.146 掲載の参考文献
1) Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007 ; 21 : 1907-14.
PubMed
2) Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016 ; 375 : 740-53.
PubMed
3) Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 ; 376 : 836-47.
PubMed
4) Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 ; 378 : 439-48.
 
5) Park JH, Riviere I, Gonen M, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018 ; 378 : 449-59.
PubMed
6) Leonard J, Stock W. Progress in adult ALL : incorporation of new agents to frontline treatment. Hematology Am Soc Hematol Educ Program. 2017 ; 1 : 28-36.
PubMed
7) Qasim W, Zhan H, Samarasinghe S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med. 2017 ; 9.
 
8) Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 ; 371 : 1005-15.
PubMed
9) Iacobucci I, Mullighan CG. Genetic basis of acute lymphoblastic leukemia. J Clin Oncol. 2017 ; 35 : 975-83.
PubMed
10) Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities. Nat Rev Clin Oncol. 2018 ; 15 : 47-62.
PubMed
11) Kebriaei P, Cutler C, de Lima M, et al. Management of important adverse events associated with inotuzumab ozogamicin : expert panel review. Bone Marrow Transplant. 2018 ; 53 : 449-56.
 
P.151 掲載の参考文献
1) Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003 ; 21 : 774-80.
PubMed
2) Hayakawa F, Sakura T, Yujiri T, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014 ; 4 : e252.
 
3) Yasuda T, Tsuzuki S, Kawazu M, et al. Recurrent DUX4 fusions in B cell acute lymphoblastic leukemia of adolescents and young adults. Nat Genet. 2016 ; 48 : 569-74.
 
4) Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2010 ; 2010 : 21-9.
 
5) Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : the GRAALL-2003 study. J Clin Oncol. 2009 ; 27 : 911-8.
 
6) Storring JM, Minden MD, Kao S, et al. Treatment of adults with BCR-ABL negative acute lymphoblastic leukaemia with a modified paediatric regimen. Br J Haematol. 2009 ; 146 : 76-85.
PubMed
7) Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol. 2008 ; 26 : 1843-9.
 
8) DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 ; 29 : 526-34.
PubMed
9) Toft N, Birgens H, Abrahamsson J, et al. Results of NOPHO ALL2008 treatment for patients aged 1-45 years with acute lymphoblastic leukemia. Leukemia. 2018 ; 32 : 606-15.
PubMed
10) Roberts KG, Li Y, Payne-Turner D, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med. 2014 ; 371 : 1005-15.
PubMed
11) Kantarjian H, Stein A, Gokbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 ; 376 : 836-47.
PubMed
12) Kantarjian H, Deangelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic Leukemia. N Engl J Med. 2016 : 375 : 740-53.
PubMed
13) Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 : 378 ; 439-48.
 
P.158 掲載の参考文献
1) Pui CH, Yang JJ, Hunger SP, et al. Childhood acute lymphoblastic leukemia : Progress through collaboration. J Clin Oncol. 2015 ; 33 : 2938-48.
PubMed
2) Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia : the GRAALL- 2003 study. J Clin Oncol. 2009 ; 27 : 911-8.
PubMed
3) Hayakawa F, Sakura T, Yujiri T, et al. Markedly improved outcomes and acceptable toxicity in adolescents and young adults with acute lymphoblastic leukemia following treatment with a pediatric protocol : a phase II study by the Japan Adult Leukemia Study Group. Blood Cancer J. 2014 ; 4 : e252.
 
4) DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 ; 29 : 526-34.
PubMed
5) Sakura T, Hayakawa F, Sugiura I, et al. High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia : a phase III study by JALSG. Leukemia. 2018 ; 32 : 626-32.
PubMed
6) O'Brien S, Thomas DA, Ravandi F, et al. Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia. Cancer. 2008 ; 113 : 2097-101.
PubMed
7) Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL) : results from the international MRC UKALL ?/ECOG2993 trial. Br J Haematol. 2012 ; 157 : 463-71.
PubMed
8) Geyer MB, Hsu M, Devlin SM, et al. Overall survival among older US adults with ALL remains low despite modest improvement since 1980 : SEER analysis. Blood. 2017 ; 129 : 1878-81.
PubMed
9) Gokbuget N. How I treat older patients with ALL. Blood 2013 ; 122 : 1366-1375.
 
10) Hurria A, Cirrincione CT, Muss HB, et al. Implementing a geriatric assessment in cooperative group clinical cancer trials : CALGB 360401. J Clin Oncol. 2011 ; 29 : 1290-6.
PubMed
11) Japan Clinical Oncology Group 高齢者研究Geriatric research-JCOG. http://www.jcog.jp/basic/policy/A_020_0010_39.pdf, Jun 15, 2018, Access
 
12) Kantarjian H, Ravandi F, Short NJ, et al. Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia : a single-arm, phase 2 study. Lancet Oncol. 2018 ; 19 : 240-48.
 
13) Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL) ; an MRC UKALL12/ECOG 2993 study. Blood. 2007 ; 109 : 944-50.
PubMed
14) Kantarjian HM, Stein AS, Bargou RC, et al. Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia : Results from 2 phase 2 studies. Cancer. 2016 ; 122 : 2178-85.
PubMed
15) Jabbour EJ, DeAngelo DJ, Stelljes M, et al. Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE. Cancer. 2018 ; 124 : 1722-32.
PubMed
16) Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 ; 18 : 547-61.
PubMed
17) Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016 ; 375 : 740-753.
PubMed
P.164 掲載の参考文献
1) Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 ; 376 : 917-27.
PubMed
2) 日本血液学会, 編. 4. 慢性骨髄性白血病/骨髄増殖性腫瘍. In : 造血器腫瘍診断ガイドライン 2018年版. 東京 : 金原出版 : 2018. p.89-120.
 
3) Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of dasision : the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016 ; 34 : 2333-40.
 
4) Hocchaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia. 2016 ; 30 : 1044-54.
 
5) Cortes JE, Gambacorti-Passerini C, Deininger MW, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia : results from the Randomized BFORE trial. J Clin Oncol. 2017 ; 36 : 231-7.
 
6) Beccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia : 2013. Blood. 2013 ; 122 : 872-84.
 
P.173 掲載の参考文献
1) NCCN Clinical Practice Guidelines in Oncology. Chronic Myeloid Leukemia (NCCN Evidence Blocks) 2018. https://www.nccn.org/professionals/physician_gls/pdf/cml_blocks.pdf
 
2) Giles FJ, le Coutre PD, Pinilla-Ibarz J, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase : 48-month follow-up results of a phase II study. Leukemia. 2013 ; 27 : 107-12.
 
3) Shah NP, Rousselot P, Schiffer C, et al. Dasatinib in imatinib-resistant or-intolerant chronic-phase, chronic myeloid leukemia patients : 7-year follow-up of study CA180-034. Am J Hematol. 2016 ; 91 : 869-74.
 
4) Cortes JE, Khoury HJ, Kantarjian HM, et al. Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib. Am J Hematol. 2016 ; 91 : 1206-14.
PubMed
5) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 ; 369 : 1783-96.
 
6) Jabbour E, Kantarjian H. Chronic myeloid leukemia : 2018 update on diagnosis, therapy and monitoring. Am J Hematol. 2018 ; 93 : 442-9.
PubMed
P.176 掲載の参考文献
1) Jain P, Kantarjian HM, Ghorab A, et al. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blastic phase in the tyrosine kinase inhibitoe era : Cohort study of 477 patients. Cancer. 2017 ; 123 : 4319-402.
 
2) Nicolini FE, Basak GW, Kim D-W, et al. Overall survival with ponatinibversus allogenic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. 2017 ; 123 : 2875-80.
PubMed
3) Boddu P, Shah AR, Borthakur G, et al. Life after ponatinib failure : outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leukemia & lymphoma. 2018 ; 59 : 1312-22.
PubMed
P.184 掲載の参考文献
1) Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017 ; 376 : 917-27.
PubMed
2) Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006 ; 354 : 2531-41.
PubMed
3) Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006 ; 354 : 2542-51.
 
4) Cortes JE, Kantarjian HM, Brummendorf TH, et al. Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib. Blood. 2011 ; 118 : 4567-76.
 
5) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013 ; 369 : 1783-96.
 
6) Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION : The dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients Trial. J Clin Oncol. 2016 ; 34 : 2333-40.
 
7) Hochhaus A, Saglio G, Hughes TP, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase : 5-year update of the randomized ENESTnd trial. Leukemia. 2016 ; 30 : 1044-54.
PubMed
8) Gambacorti-Passerini C, Cortes JE, Lipton JH, et al. Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia. Am J Hematol. 2014 ; 89 : 947-53.
PubMed
9) Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia : final 5-year results of the phase 2 PACE trial. Blood. 2018 ; 132 : 393-404.
PubMed
10) Douxfils J, Haguet H, Mullier F, et al. Association between BCR-ABL tyrosine kinase inhibitors for chronic myeloid leukemia and cardiovascular events, major molecular response, and overall survival a systematic review and meta-analysis. JAMA Oncol. 2016 ; 2 : 625-32.
PubMed
11) Chai-Adisaksopha C, Lam W, Hillis C. Major arterial events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors : a meta-analysis. Leuk Lymphoma. 2016 ; 57 : 1300-10.
PubMed
12) Cortes JE, Gambacorti-Passerini C, Kim DW, et al. Effects of bosutinib treatment on renal function in patients with Philadelphia chromosome-positive leukemias. Clin Lymphoma Myeloma Leuk. 2017 ; 17 : 684-95.
PubMed
13) Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol. 2015 ; 90 : 1060-4.
PubMed
14) Barber MC, Mauro MJ, Moslehi J. Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy. Hematology Am Soc Hematol Educ Program. 2017 ; 110-4.
PubMed
P.189 掲載の参考文献
1) Sasaki K, Strom S, O'Brien S, et al. Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era : analysis of patient data from six prospective clinical trials. Lancet Haematol. 2015 ; 2 : e186-93.
 
2) Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years : the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010 ; 11 : 1029-35.
PubMed
3) Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014 ; 32 : 424-30.
 
4) Imagawa J, Tanaka H, Okada M, et al. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial) : a multicentre phase 2 trial. Lancet Haematol. 2015 ; 2 : e528-35.
 
5) 日本血液学会, 編. 造血器腫瘍診療 2018年版. 東京 : 金原出版 ; 2018
 
6) Hochhaus A, Saussele S, Rosti G, et al. Chronic myeloid leukaemia : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017 ; 28 : iv41-iv51.
PubMed
7) Takahashi N, Tauchi T, Kitamura K, et al. Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia : the JALSG-STIM213 study. Int J Hematol. 2018 ; 107 : 185-93.
PubMed
8) Rea D, Nicolini FE, Tulliez M, et al. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia : interim analysis of the STOP 2G-TKI study. Blood. 2017 ; 129 : 846-54.
PubMed
9) Okada M, Imagawa J, Tanaka H, et al. Final 3-year results of the dasatinib discontinuation trial in patients with chronic myeloid leukemia who received dasatinib as a second line treatment. Clin Lymphoma Myeloma Leuk. 2018 ; 18 : 353-60.
PubMed
P.194 掲載の参考文献
1) Vainchenker W, Delhommeau F, Constantinescu SN, et al. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011 ; 118 : 1723-35.
PubMed
2) Vainchenker W, Kralovics R. Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms. Blood. 2017 ; 129 : 667-79.
PubMed
3) Shih AH, Abdel-Wahab O, Patel JP, et al. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012 ; 12 : 599-612.
PubMed
4) Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016 ; 127 : 325-32.
PubMed
5) Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016 ; 127 : 333-42.
PubMed
6) Ortmann CA, Kent DG, Nangalia J, et al. Effect of mutation order on myeloproliferative neoplasms. N Engl J Med. 2015 ; 372 : 601-12.
PubMed
7) Nangalia J, Nice FL, Wedge DC, et al. DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype. Haematologica. 2015 ; 100 : e438-42.
PubMed
8) Tefferi A, Lasho TL, Guglielmelli P, et al. Target deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances. 2016 ; 1 : 21-30.
PubMed
9) Vannucchi AM, Lasho TL, Guglielmelli P, et al. Mutations and prognosis in primary myelofibrosis. Leukemia. 2013 ; 27 : 1861-9.
PubMed
10) Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera : an international study. Leukemia. 2013 ; 27 : 1874-8.
 
11) Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment. Blood. 2012 ; 120 : 1197-201.
 
12) Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 ; 113 : 2895-901.
 
13) Gangat N, Caramazza D, Vaidya R, et al. DIPSS Plus : A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status. J Clin Oncol. 2011 ; 29 : 392-7.
 
P.202 掲載の参考文献
1) Mesa RA, Jamieson C, Bhatia R, et al. NCCN Guidelines Insights : Myeloproliferative neoplasms, version 2.2018. J Natl Compr Canc Netw. 2017 ; 15 : 1193-207.
PubMed
2) Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms : revised management recommendations from European LeukemiaNet. Leukemia. 2018 ; 32 : 1057-69.
PubMed
3) Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2) : a randomised, open-label, phase 3b study. Lancet Oncol. 2017 ; 18 : 88-99.
PubMed
4) Griesshammer M, Saydam G, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly : 80-week follow-up from the RESPONSE-2 trial. Ann Hematol. 2018.
PubMed
5) Kirito K, Suzuki K, Miyamura K, et al. Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. Int J Hematol. 2018 ; 107 : 173-84.
PubMed
6) Mesa R, Vannucchi AM, Yacoub A, et al. The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera : a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 ; 176 : 76-85.
PubMed
7) Barbui T, Vannucchi AM, Finazzi G, et al. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera : A propensity-matched study. Am J Hematol. 2017 ; 92 : 1131-6.
PubMed
8) Lussana F, Cattaneo M, Rambaldi A, et al. Ruxolitinib-associated infections : A systematic review and meta-analysis. Am J Hematol. 2017 ; 93 : 339-47.
PubMed
P.207 掲載の参考文献
1) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018. 東京 : 金原出版 ; 2018.
 
2) Birgegard G, Besses C, Griesshammer M, et al. Treatment of essential thrombocythemia in Europe : a prospective long-term observational study of 3649 high-risk patients in the evaluation of anagrelide efficacy and long-term safety study Haematologica. 2018 ; 103 : 51-60.
PubMed
3) Dombi P, Illes A, Demeter J, et al. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin. Eur J Haematol. 2017 ; 98 : 106-11.
PubMed
4) Landolfi R, Di Gennaro L. Prevention of thrombosis in PV and ET. Haematologica. 2008 ; 93 : 331-5.
 
5) Rey J, Viallard JF, Keddad K, et al. Characterization of different regimens for initiating anagrelide in patients with essential thrombocythemia who are intolerant or refractory to their current cytoreductive therapy : results from the multicenter FOX study of 177 patients in France. Eur J Haematol. 2014 ; 92 : 127-36.
PubMed
6) Iurlo A, Cattaneo D, Orofino N, et al. Anagrelide and mutational status in essential thrombocythemia. BioDrugs 2016 ; 30 : 219-23.
PubMed
7) Cascavilla N, De Stefano V, Pane F, et al. Impact of JAK2 (V617F) mutation status on treatment response to anagrelide in essential thrombocythemia : an observational, hypothesis-generating study. Drug Des Devel Ther. 2015 ; 9 : 2687-94.
PubMed
8) Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 ; 2391-2405.
 
9) Swerdlow SH, et al ed. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon : IARC press ; 2008. p.40-50.
 
10) Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis- an international study. J Clin Oncol. 2011 ; 29 : 3179-84.
 
P.214 掲載の参考文献
1) Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 ; 113 : 2895-901.
 
2) Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis : a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 ; 115 : 1703-8.
 
3) Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus : a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 ; 29 : 392-7.
 
4) Takenaka K, Shimoda K, Uchida N, et al. Clinical features and outcomes of patients with primary myelofibrosis in Japan : report of a 17-year nationwide survey by the Idiopathic Disorders of Hematopoietic Organs Research Committee of Japan. Int J Hematol. 2017 ; 105 : 59-69.
PubMed
5) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
 
6) Devlin R, Gupta V. Myelofibrosis : to transplant or not to transplant? Hematology. 2016 : 543-51.
 
7) Kroger N, Giorgino T, Scott BL, et al. Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood. 2015 ; 125 : 3347-50.
PubMed
8) Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012 ; 366 : 799-807.
PubMed
9) Verstovsek S, Mesa RA, Gotlib J, et al. Long-term treatment with ruxolitinib for patients with myelofibrosis : 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017 ; 10 : 55-68.
 
10) Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012 ; 366 : 787-98.
PubMed
11) Harrison CN, Vannucchi AM, Kiladjian JJ, et al. Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis. Leukemia. 2016 ; 30 : 1701-7.
 
12) Verstovsek S, Gotlib J, Mesa RA, et al. Long-term survival in patients treated with ruxolitinib for myelofibrosis : COMFORT-I and-II pooled analyses. J Hematol Oncol. 2017 ; 10 : 156-61.
PubMed
13) Shahnaz Syed Abd Kadir S, Christopeit M, Gerald W, et al. Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis. Eur J Haematol. 2018. Epub ahead of print.
 
14) Newberry KJ, Patel K, Masarova L, et al. Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation. Blood. 2017 ; 130 : 1125-31.
PubMed
15) Talpaz M, Paquette R, Afrin L, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. J Hematol Oncol. 2013 ; 6 : 81-90.
PubMed
16) Yogarajah M, Tefferi A. Leukemic transformation in myeloproliferative neoplasms : a literature review on risk, characteristics, and outcome. Mayo Clin Proc. 2017 ; 92 : 1118-28.
PubMed
17) Rumi E, Pietra D, Pascutto C, et al. Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood. 2014 ; 124 : 1062-9.
PubMed
18) Patel KP, Newberry KJ, Luthra R, et al. Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib. Blood. 2015 ; 126 : 790-7.
PubMed
P.220 掲載の参考文献
1) Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome : analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975 ; 54 : 1-27.
PubMed
2) Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. 2017 ; 129 : 704-14.
PubMed
3) Panch SR, Bozik ME, Brown T, et al. Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes. Blood. 2018. Epub ahead of print.
 
4) Gotlib J. World Health Organization-defined eosinophilic disorders : 2017 ; update on diagnosis, risk stratification, and management. Am J Hematol. 2017 ; 92 : 1243-59.
PubMed
5) Klion AD. How I treat hypereosinophilic syndromes. Blood. 2015 ; 126 : 1069-77.
 
6) Rumi E, Milosevic JD, Selleslag D, et al. Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Ann Hematol. 2015 ; 94 : 1927-8.
PubMed
7) Helbig G, Hus M, Halasz M, et al. Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome. Med Oncol. 2012 ; 29 : 1073-6.
 
8) Khoury P, Desmond R, Pabon A, et al. Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome. Allergy. 2016 ; 71 : 803-10.
PubMed
9) Pardanani A, Lasho T, Wassie E, et al. Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing. Leukemia. 2016 ; 30 : 1924-6.
PubMed
10) Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008 ; 358 : 1215-28.
PubMed
11) Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013 ; 131 : 461-7.
PubMed
12) Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014 ; 371 : 2488-98.
PubMed
13) Helbig G, Wisniewska-Piaty K, Francuz T, et al. Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome : Retrospective study in 33 patients. Leuk Lymphoma. 2013 ; 54 : 807-11.
PubMed
P.224 掲載の参考文献
1) McNally RJ, Roman E, Cartwright RA. Leukemias and lymphomas : time trends in the UK, 1984-93. Cancer Causes Control. 1999 ; 10 : 35-42.
PubMed
2) Aviles A, Neri N, Nambo MJ. Hematological malignancies and pregnancy : treat or no treat during first trimester. Int J Cancer. 2012 ; 131 : 2678-83.
 
3) Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thrombosis Research. 2013 ; 131 : S11-S3.
PubMed
4) Paydas S. Management of hemopoietic neoplasias during pregnancy. Crit Rev Oncol Hematol. 2016 ; 104 : 52-64.
PubMed
5) Griesshammer M, Struve S, Harrison CM. Essential thrombocythemia/polycythemia vera and pregnancy : the need for an observational study in Europe. Semin Thromb Hemost. 2006 ; 32 (4 Pt 2) : 422-9.
 
6) Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica. 2004 ; 89 : 215-32.
 
7) Elliott MA, Tefferi A. Thrombocythaemia and pregnancy. Best Pract Res Clin Haematol. 2003 ; 16 : 227-42.
PubMed
8) Harrison C. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005 ; 129 : 293-306.
PubMed
9) Barbui T, Barosi G, Birgegard G, et al. Philadelphia-negative classical myeloproliferative neoplasms : critical concepts and management recommendations from European Leukemia-Net. J Clin Oncol. 2011 ; 29 : 761-70.
 
10) Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015 ; 26 Suppl 5 : v85-99.
 
11) Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008 ; 22 : 235-45.
PubMed
12) Gangat N, Wolanskyj AP, Schwager S, et al. Predictors of pregnancy outcome in essential thrombocythemia : a single institution study of 63 pregnancies. Euro J Haematol. 2009 ; 82 : 350-3.
 
13) Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617 V > F) mutation. Blood. 2007 ; 110 : 485-9.
 
14) Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia : a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010 ; 8 : 411-3.
PubMed
15) Rumi E, Bertozzi I, Casetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015 ; 100 : e443-5.
PubMed
16) Reilly JT, McMullin MF, Beer PA, et al. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012 ; 158 : 453-71.
PubMed
17) Melillo L, Tieghi A, Candoni A, et al. Outcome of 122 pregnancies in essential thrombocythemia patients : A report from the Italian registry. Am J Hematol. 2009 ; 84 : 636-40.
PubMed
18) Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms : UK prospective cohort study. Br J Haematol. 2016 ; 175 : 31-6.
PubMed

IV. リンパ系腫瘍

P.232 掲載の参考文献
1) Hallek M, Cheson BD, Catovsky D, et al. iwCLL Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018 ; 131 : 2745-60.
PubMed
2) Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 ; 111 : 5446-56.
 
3) The International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI) : a meta-analysis of individual patient data. Lancet Oncol. 2016 ; 17 : 779-90.
 
4) Hallek M. Chronic lymphocytic leukemia : 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 ; 92 : 946-965.
PubMed
5) Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL : 5-year follow-up of a phase 2 study. Blood. 2018 ; 131 : 2357-66.
PubMed
6) Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia : a randomised, open-label, phase 3 trial. Lancet. 2010 ; 376 : 1164-74.
PubMed
7) Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10) : an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016 ; 17 : 928-42.
PubMed
8) Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic Lymphocytic Leukemia. N Engl J Med. 2015 ; 373 : 2425-37.
PubMed
9) Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL : updated results of the CLL8 trial. Blood. 2016 ; 127 : 208-15.
PubMed
10) NCCN Guidelines. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 2018 version 5. https://www.nccn.org/
 
11) Esmo Guidelines Committee. Appendix 4 : Chronic lymphocytic leukaemia : eUpdate published online 27 June 2017 (www.esmo.org/Guidelines/Haematological-Malignancies). Ann Oncol. 2017 ; 28 (suppl_4) : iv149-52.
 
P.238 掲載の参考文献
1) Hallek M. Chrnonic lymphocytic leukemia : 2017 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2017 ; 92 : 946-65.
PubMed
2) Hallek M, Cheson BD, Catovsky D, et al. International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia : a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008 ; 111 : 5446-56.
 
3) Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010 ; 28 : 1756-65.
PubMed
4) Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia : a randomized phase 3 trial. Lancet Oncol. 2012 ; 12 : 1204-13.
 
5) Fischer K, CramerP, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia : A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011 ; 29 : 3559-66.
 
6) Byrd JC, Brown JR, O'brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014 ; 371 : 213-23.
PubMed
7) Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS) : a randomised, double-blind, phase 3 study. Lancet Oncol. 2016 ; 17 : 200-11.
 
8) Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use : a systematic review and meta-analysis. Blood. 2016 ; 128 : 138-40.
PubMed
9) Shustik C, Bence-Bruckler I, Delage R, et al. Advances in the treatment of relapsed/refractory chronic lymphocytic leukemia. Ann Hematol. 2017 ; 96 : 1185-96.
PubMed
10) Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013 ; 369 : 32-42.
PubMed
11) Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014 ; 123 : 3390-7.
PubMed
12) Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016 ; 374 : 311-22.
PubMed
13) Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion : a multicentre, open-label, phase 2 study. Lancet Oncol. 2016 ; 17 : 768-78.
 
14) Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014 ; 370 : 997-1007.
PubMed
15) Zelenetz AD, Barrientos JC, Brown JR, et al. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia : interim results from phase 3, randomized, double-blind, placebo-controlled trial. Lancet Oncol. 2017 ; 18 : 297-311.
 
16) Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 ; 378 : 1107-20.
 
17) Woyach JA, Furman RR, Liu TM, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med. 2014 ; 370 : 2286-94.
PubMed
18) Dreger P, Schetelig J, Andersen N, et al. Managing high-risk CLL during transition to a new treatment era : stem cell transplantation or novel agents? Blood. 2014 ; 124 : 3841-9.
PubMed
19) Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines Committee of the American Society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2016 ; 22 : 2117-25.
 
P.244 掲載の参考文献
1) Hallek, M, Cheson BD, Catovsky D, et al. Guidelines for diagnosis, indications for treatment, response assessment and supportive management of chronic lymphocytic leukemia. Blood. 2018. Epub ahead of print.
 
2) Dimier N, Delmar P, Ward C, et al. A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 ; 131 : 955-62.
 
3) Rigolin GM, Saccenti E, Guardalben E, et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. Br J Haematol. 2018 ; 181 : 229-33.
PubMed
4) Ahn IE, Farooqui MZH, Tian X, et al. Depth and durability of response to ibrutinib in CLL : 5-year follow-up of a phase 2 study. Blood. 2018 ; 131 : 2357-66.
PubMed
5) Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion : results from the full population of a phase II pivotal trial. J Clin Oncol. 2018 ; 36 : 1973-80.
 
6) Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014 ; 370 : 1101-10.
PubMed
7) Goede V, Fischer K, Engelke A, et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia : updated results of the CLL11 study. Leukemia. 2015 ; 29 : 1602-4.
PubMed
8) O'Brien S, Furman RR, Coutre S, et al. Single-agent ibrutinib in treatment-naive and relapsed/refractory chronic lymphocytic leukemia : a 5-year experience. Blood. 2018 ; 131 : 1910-9.
PubMed
9) Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018 ; 378 : 1107-20.
 
10) Fischer K, Al-Sawaf O, Fink A-M, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 ; 129 : 2702-5.
PubMed
P.249 掲載の参考文献
1) Rossi D, Spina V, Gaidano G. Biology and treatment of Richter syndrome. Blood. 2018 ; 131 : 2761-72.
PubMed
2) Parikh SA, Kay NE, Shanafelt TD. How we treat Richter syndrome. Blood. 2014 ; 123 : 1647-57.
PubMed
3) Falchi L, Keating MJ, Marom EM, et al. Correlation between FDG/PET, histology, characteristics and survival in 332 patients with chronic lymphoid leukemia. Blood. 2014 ; 123 : 2783-90.
PubMed
4) Tsimberidou AM, O'Brien S, Khouri I, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006 ; 24 : 2343-51.
 
5) Cwynarski K, van Biezen A, de Wreede L, et al. Autologous and allogeneic stem-cell transplantation for transformed chronic lymphocytic leukemia (Richter's syndrome) : A retrospective analysis from the chronic lymphocytic leukemia subcommittee of the chronic leukemia working party and lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2012 ; 30 : 2211-7.
 
6) Langerbeins P, Busch R, Anheier N, et al. Poor efficacy and tolerability of R-CHOP in relapsed/refractory chronic lymphocytic leukemia and Richter transformation. Am J Hematol. 2014 ; 89 : E239-43.
PubMed
7) Eyre TA, Clifford R, Bloor A, et al. NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome. Br J Haematol. 2016 ; 175 : 43-54.
PubMed
8) Tsang M, Shanafelt TD, Call TG, et al. The efficacy of ibrutinib in the treatment of Richter syndrome. Blood. 2015 ; 125 : 1676-8.
PubMed
9) Rossi D, Spina V, Deambrogi C, et al. The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. Blood. 2011 ; 117 : 3391-401.
PubMed
10) Eyre TA, Schuh A. An update for Richter syndrome- new directions and developments. Br J Haematol. 2017 ; 178 : 508-20.
PubMed
P.254 掲載の参考文献
1) Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa : a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 1997 ; 15 : 1110-7.
PubMed
2) Solal-Celigny P, Lepage E, Brousse N, et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas : final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol. 1998 ; 16 : 2332-8.
 
3) Sebban C, Mounier N, Brousse N, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma : the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood. 2006 ; 108 : 2540-4.
 
4) Ardeshna KM, Smith P, Norton A, et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma : a randomised controlled trial. Lancet. 2003 ; 362 : 516-22.
PubMed
5) Ardeshna KM, Qian W, Smith P, et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma : an open-label randomised phase 3 trial. Lancet Oncol. 2014 ; 15 : 424-35.
PubMed
6) Colombat P, Brousse N, Salles G, et al. Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma : survival analyses with 7-year follow-up. Ann Oncol. 2012 ; 23 : 2380-5.
 
7) Kahl BS, Hong F, Williams ME, et al. Results of Eastern Cooperative Oncology Group Protocol E4402 (RESORT) : A randomized phase III study comparing two different rituximab dosing strategies for low tumor burden follicular lymphoma. ASH Annual Meeting Abstracts. 2011 ; 118 : LBA.
 
8) Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma : ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 ; 27 : v83.
PubMed
P.258 掲載の参考文献
1) Pastore A, Jurinovic V, Kridel R. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma : a retrospective analysis of a prospective clinical trial and validation in a population-based registry. Lancet Oncol. 2015 ; 16 : 1111-22.
 
2) Huet S, Tesson B, Jais JP, et al. A gene-expression profiling score for prediction of outcome in patients with follicular lymphoma : a retrospective training and validation analysis in three international cohorts. Lancet Oncol. 2018 ; 19 : 549-61.
 
3) Casulo C, Byrtek M, Dawson KL, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death : An Analysis from the National LymphoCare Study. J Clin Oncol. 2015 ; 33 : 2516-22.
PubMed
4) Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone : results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005 ; 106 : 3725-32.
 
5) Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008 ; 26 : 4579-86.
PubMed
6) Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma : a systematic review and meta-analysis. J Natl Cancer Inst. 2007 ; 99 : 706-14.
PubMed
7) Federico M, Luminari S, Dondi A, et al. R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma : results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. J Clin Oncol. 2013 ; 31 : 1506-13.
PubMed
8) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 noninferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
9) Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA) : a phase 3, randomised controlled trial. Lancet. 2011 ; 377 : 42-51.
 
10) Marcus R, Davies A, Ando K, et al. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma. N Engl J Med. 2017 ; 377 : 1331-44.
PubMed
11) Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL : the BRIGHT study. Blood. 2014 ; 123 : 2944-52.
 
12) Rummel MJ, Maschmeyer G, Ganser A, et al. Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as first-line treatment in patients with indolent lymphomas : Nine-year updated results from the StiL NHL1 study [abstract]. J Clin Oncol. 2017 ; abstract no. 7501
 
13) Flinn IW, et al. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP : Results of the BRIGHT 5-year follow-up study [abstract]. J Clin Oncol. 2017 ; abstract no. 7500.
 
14) Hiddemann W, Barbui AM, Canales MA, et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study : Influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018. Epub ahead of print.
PubMed
15) Ohmachi K, Tobinai K, Kinoshita T, et al. Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma : a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial. Int J Hematol. 2018. 36 : 2395-404.
 
16) Fowler NH, Morschhauser F, Feugier P, et al. RELEVANCE : Phase III randomized study of lenalidomide plus rituximab (R2) versus chemotherapy plus rituximab, followed by rituximab maintenance, in patients with previously untreated follicular lymphoma [abstract]. J Clin Oncol. 2018 ; abstract no. 7500.
 
P.264 掲載の参考文献
1) Link BK, Maurer MJ, Nowakowski GS, et al. Rates and outcome of follicular lymphoma transformation in the immunochemotherapy era : a report from the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource. J Clin Oncol. 2013 ; 31 : 3272-8.
 
2) Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab : a Japanese phase II study. Ann Oncol. 2002 ; 13 : 928-43.
PubMed
3) Tobinai K, Igarashi T, Itoh K, et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B-cell non-Hodgkin lymphoma mostly pretreated with rituximab : a multicenter phase II study. Cancer Sci. 2011 ; 102 : 1698-705.
 
4) Rummel M, Kaiser U, Balser C, et al. Bendamustine plus versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas : a multicenter, randomized, open-label, non-inferiority phase 3 trial. Lancet Oncol. 2016 ; 17 : 57-66.
PubMed
5) Sehn LH, Chua N, Mayer J, et al. Obinutuzumab plus bendamusitne versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN) : a randomized, controlled, open-label, muticentre, phase 3 trial. Lancet Oncol. 2016 ; 17 : 1081-93.
 
6) Cheson BD, Chua N, Mayer J, et al. Overall survival benefit in patients with rituximab-refractory indolent non-Hodgkin lymphoma who received obinutuzumab plus bendamustine induction and obinutuzumab maintenance in the GADOLIN study. J Clin Oncol. 2018 ; 36 : 2259-66.
PubMed
7) Tobinai K, Watanabe T, Ogura M, et al. Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2006 ; 24 : 174-80.
PubMed
8) Tobinai K, Ishizawa K, Ogura M, et al. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci. 2009 ; 100 : 1951-6.
PubMed
9) Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol. 2002 ; 20 : 2453-63.
 
10) Witzig TE, Flinn IW, Gordon LI, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol. 2002 ; 20 : 3262-9.
PubMed
11) Witzig TE, Molina A, Gordon LI, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer. 2007 ; 109 : 1804-10.
PubMed
12) Kuruvilla J, MacDonald DA, Kouroukis CT, et al. Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma : a subset analysis of NCIC CTG LY12. Blood. 2015 ; 126 : 733-8.
PubMed
P.269 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition, Lyon : IARC Press ; 2017.
 
2) 岡本昌隆, 新津望, 三浦偉久男, 他. 2,000例を越える連続登録例の中央診断に基づいた悪性リンパ腫の病型頻度-WHO分類第4版もふまえて-. 日本リンパ網内系学会会誌. 2009 ; 49 : 86.
 
3) Khalil MO, Morton LM, Devesa SS, et al. Incidence of marginal zone lymphoma in the United States, 2001-2009 with a focus on primary anatomic site. Br J Haematol. 2014, 165, 67-77.
PubMed
4) Arcaini L, Burcheri S, Rossi A, et al. Nongastric marginal-zone B-cell MALT lymphoma : prognostic value of disease dissemination. Oncologist. 2006 ; 11 : 285-91.
 
5) Raderer M, Wohrer S, Streubel B, et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging : a single-center experience. J Clin Oncol. 2006, 24 : 3136-41.
PubMed
6) Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003, 101 : 2489-95.
PubMed
7) Doglioni C, Wotherspoon A, Moschini A, et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet. 1992 ; 339 : 834-5.
PubMed
8) Nakamura S, Sugiyama T, Matsumoto T, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori : a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012 ; 61 : 507-13.
PubMed
9) Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004 ; 350 : 239-48.
PubMed
10) Ferreri AJ, Guidoboni M, Ponzoni M, et al. Evidence for an association between Chlamydia psittaci and ocular adnexal lymphomas. J Natl Cancer Inst. 2004 ; 96 : 586-94.
PubMed
11) Cerroni LJ, Zochling N, Putz B, et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. Cutan Pathol. 1997 ; 24 : 457-61.
 
12) Sena Teixeira Mendes L, D Attygalle A, C Wotherspoon A. Helicobacter pylori infection in gastric extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphoma : a re-evaluation. Gut. 2014 ; 63 : 1526-7.
PubMed
13) Zucca E, Bertoni F. The spectrum of MALT lymphoma at different sites : biological and therapeutic relevance. Blood. 2016 ; 127 : 2082-92.
PubMed
14) Sugizaki K, Tari A, Kitadai Y, et al. Anti-Helicobacter pylori therapy in localized gastric mucosa-associated lymphoid tissue lymphoma : A prospective, nationwide, multicenter study in Japan. Helicobacter. 2018 ; 23 : e12474.
PubMed
15) Ruskone-Fourmestraux A, Matysiak-Budnik T, Fabiani B, et al. Exclusive moderate-dose radiotherapy in gastric marginal zone B-cell MALT lymphoma : Results of a prospective study with a long term follow-up. Radiother Oncol. 2015 ; 117 : 178-82.
 
16) Asano N, Iijima K, Koike T, et al. Helicobacter pylori-negative gastric mucosa-associated lymphoid tissue lymphomas : A review. World J Gastroenterol. 2015 ; 21 : 8014-20.
PubMed
17) Tsang RW, Gospodarowicz MK, Pintilie M, et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol. 2003 ; 21 : 4157-64.
PubMed
18) Salar A, Domingo-Domenech E, Panizo C, et al. First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01) : a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2014 ; 1 : e104-11.
PubMed
19) Salar A, Domingo-Domenech E, Panizo C, et al. Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma. Blood. 2017 ; 130 : 1772-4.
PubMed
20) Zucca E, Conconi A, Laszlo D, et al. Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma : 5-year analysis of the IELSG-19 Randomized Study. J Clin Oncol. 2013 ; 31 : 565-72.
 
21) Zucca E, Conconi A, Martinelli G, et al. Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma : improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy. J Clin Oncol. 2017 ; 35 : 1905-12.
PubMed
22) Thieblemont C, Cascione L, Conconi A, et al. A MALT lymphoma prognostic index. Blood. 2017 ; 130 : 1409-17.
PubMed
23) Noy A, de Vos S, Thieblemont C, et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma. Blood. 2017 ; 129 : 2224-32.
PubMed
24) Kiesewetter B, Troch M, Dolak W, et al. A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma). Haematologica. 2013 ; 98 : 353-6.
PubMed
25) Conconi A, Martinelli G, Lopez-Guillermo A, et al. Clinical activity of bortezomib in relapsed/refractory MALT lymphomas : results of a phase II study of the International Extranodal Lymphoma Study Group (IELSG). Ann Oncol. 2011 ; 22 : 689-95.
 
26) Gopal AK, Kahl BS, de Vos S, et al. PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma. N Engl J Med. 2014 ; 370 : 1008-18.
 
P.275 掲載の参考文献
1) Berger F, Felman P, Thieblemont C, et al. Non-MALT marginal zone B-cell lymphomas : a description of clinical presentation and outcome in 124 patients. Blood. 2000 ; 95 : 1950-6.
 
2) Baldini L, Brugiatelli M, Luminari S, et al. Treatment of indolent B-Cell nonfollicular lymphomas : final results of the LL01 randomized trial of the Gruppo Italiano per lo Studio dei Linfomi. J Clin Oncol. 2003 ; 21 : 1459-65.
PubMed
3) Arcaini L, Vallisa D, Rattotti S, et al. Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection : a study of the Fondazione Italiana Linfomi. Ann Oncol. 2014 ; 25 : 1404-10.
PubMed
4) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
5) Laribi K, Tempescul A, Ghnaya H, et al. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma. Hematol Oncol. 2017 ; 35 : 536-41.
PubMed
6) Kang HJ, Kim WS, Kim SJ, et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy : Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol. 2012 ; 91 : 543-51.
 
7) Brown JR, Friedberg JW, Feng Y, et al. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. Br J Haematol. 2009 ; 145 : 741-8.
 
8) Kojima M, Inagaki H, Motoori T, et al. Clinical implications of nodal marginal zone B-cell lymphoma among Japanese : study of 65 cases. Cancer Sci. 2007 ; 98 : 44-9.
PubMed
9) Nathwani BN, Anderson JR, Armitage JO, et al. Marginal zone B-cell lymphoma : A clinical comparison of nodal and mucosa-associated lymphoid tissue types. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol. 1999 ; 17 : 2486-92.
PubMed
10) Traverse-Glehen A, Felman P, Callet-Bauchu E, et al. A clinicopathological study of nodal marginal zone B-cell lymphoma. A report on 21 cases. Histopathology. 2006 ; 48 : 162-73.
PubMed
11) Oh SY, Ryoo BY, Kim WS, et al. Nodal marginal zone B-cell lymphoma : Analysis of 36 cases. Clinical presentation and treatment outcomes of nodal marginal zone B-cell lymphoma. Ann Hematol. 2006 ; 85 : 781-6.
PubMed
12) Arcaini L, Paulli M, Burcheri S, et al. Primary nodal marginal zone B-cell lymphoma : clinical features and prognostic assessment of a rare disease. Br J Haematol. 2007 ; 136 : 301-4.
PubMed
13) Heilgeist A, McClanahan F, Ho AD, et al. Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma : an analysis of clinical presentation and outcome in 144 patients. Cancer. 2013 ; 119 : 99-106.
PubMed
P.281 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al, eds. WHO classification of tumours of haematopoietic and lymphoid tissues. Revised 4th edition, Lyon : IARC ; 2017.
 
2) Martin P. Optimizing therapy for mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2017 ; 304-9.
PubMed
3) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
 
4) Rule S. Frontline therapy and role of high-dose consolidation in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2016 ; 419-24.
PubMed
5) Vose JM. Mantle cell lymphoma : 2017 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2017 ; 92 : 806-13.
PubMed
6) McCulloch R, Rule S. What is the optimal initial management of the younger mantle cell lymphoma patient? Best Pract Res Clin Haematol. 2018 ; 31 : 90-8.
PubMed
7) Le Gouill S, Thieblemont C, Oberic L, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017 ; 377 : 1250-60.
PubMed
8) Hermine O, Hoster E, Walewski J, et al. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger) : a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network. Lancet. 2016 ; 388 : 565-75.
PubMed
9) Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 ; 372 : 944-53.
PubMed
10) Ruan J, Martin P, Shah B, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015 ; 373 : 1835-44.
PubMed
11) Jain P, Romaguera J, Srour SA, et al. Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL). Br J Haematol. 2018 Epub ahead of print.
 
12) Tam CS, Anderson MA, Pott C, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018 ; 378 : 1211-23.
PubMed
13) Morschhauser FA, Cartron G, Thieblemont C, et al. obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large B-cell lymphoma or mantle-cell lymphoma : results from the phase II GAUGUIN study. J Clin Oncol. 2013 ; 31 : 2912-9.
PubMed
14) Kruger WH, Hirt C, Basara N, et al. Allogeneic stem cell transplantation for mantle cell lymphoma-final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO). Ann Hematol. 2014 ; 93 : 1587-97.
 
15) Tucker DL, Peggs KS, Cook G, et al. Reduced intensity conditioned allogeneic stem cell transplantation (RIC-Allo) as front-line therapy for mantle cell lymphoma (MCL) : results from the UK Phase II Mini Allo Study (CRUK : C7627/A9080) : 19. Br J Haematol. 2016 ; 173 : 15.
 
16) Yamasaki S, Chihara D, Kim SW, et. al. Impact of hematopoietic stem cell transplantation in patients with relapsed or refractory mantle cell lymphoma. Ann Hematol. 2018 ; 97 : 1445-52.
PubMed
17) Miura K, Takasaki H, Tsujimura H, et al. Does more intensive therapy have effects on mantle cell lymphoma? A clinical experience from the Lymphoma Treatment Study Group in Japan. Int J Hematol. 2011 ; 93 : 684-6.
 
P.286 掲載の参考文献
1) Kluin-Nelemans HC, Hoster E, Hermine O, et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 ; 367 : 520-31.
PubMed
2) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
3) Robak T, Huang H, Jin J, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 ; 372 : 944-53.
PubMed
4) Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013 ; 369 : 507-16.
PubMed
5) Flinn IW, van der Jagt R, Kahl BS, et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL : the BRIGHT study. Blood. 2014 ; 123 : 2944-52.
 
6) Flinn IW, van der Jagt R, Chang J, et al. First-line treatment of iNHL or MCL patients with BR or R-CHOP/R-CVP : results of the bright 5-year follow-up study. Hematological Oncol. 2017 ; 35 : 140-1.
 
7) Wang ML, Blum KA, Martin P, et al. Long-term follow-up of MCL patients treated with single-agent ibrutinib : updated safety and efficacy results. Blood. 2015 ; 126 : 739-45.
PubMed
P.290 掲載の参考文献
1) Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 ; 381 : 1817-26.
 
2) Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study) : a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 525-33.
PubMed
3) Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma : Southwest Oncology Group study 0014. J Clin Oncol. 2008 ; 26 : 2258-63.
 
4) Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma : a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006 ; 7 : 379-91.
PubMed
P.294 掲載の参考文献
1) Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy pluse rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002 ; 346 : 235-42.
 
2) Sehn LH, Berry B, Chhnabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007 ; 109 : 1857-61.
 
3) Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 ; 116 : 2040-5.
 
4) Velasquez WS, Cabanillas F, Salvador P, et al. Effective salvage chemotherapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood. 1988 ; 71 : 117-22.
PubMed
5) Maskowitz CH, Bertino JR, Glassman JR, et al. Ifosfamide, carboplatin, and etoposide : a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol. 1999 ; 17 : 3776-85.
 
6) Philip T, Gugliemi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of salvage chemotherapy-sensitive non Hodgkin's lymphoma. N Engl J Med. 1995 ; 333 : 1540-5.
 
7) Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010 ; 28 : 4184-90.
 
8) Gisselbrecht C, Schmitz N, Mounier N, et al. Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20 (+) diffuse large B-cell lymphoma : final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol. 2012 ; 30 : 4462-9.
PubMed
9) Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas : NCIC-CTG LY. 12. J Clin Oncol. 2014 ; 32 : 3490-6.
PubMed
10) Coleman M, Martin P, Rusan J, et al. Predonisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma : low-dose metronomic, multidrug therapy. Cancer. 2008 ; 112 : 2228-32.
 
11) Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study) : a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 525-33.
PubMed
12) Cunningham D, Hawkes EA, Jack A, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma : a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013 ; 381 : 1817-26.
 
13) Vellenga E, van Putten WL, Van't Veer M, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+NHL. A prospective randomized HOVON trial. Blood. 2008 ; 111 : 537-43.
PubMed
14) Witzig TE, Geyer SM, Kurtin PJ, et al. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma : a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma. 2008 ; 49 : 1074-80.
PubMed
15) Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood. 2004 ; 103 : 3684-8.
PubMed
P.299 掲載の参考文献
1) Abel GA, Klepin HD. Frailty and the management of hematologic malignancies. Blood. 2018 ; 131 : 515-24.
PubMed
2) Buske C, Hutchings M, Ladetto M, et al. ESMO Consensus Conference on malignant lymphoma : general perspectives and recommendations for the clinical management of the elderly patient with malignant lymphoma. Ann Oncol. 2018 ; 29 : 544-62.
PubMed
3) Delarue R, Tilly H, Mounier N, et al. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study) : a randomised phase 3 trial. Lancet Oncol. 2013 ; 14 : 525-33.
PubMed
4) Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma : a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011 ; 12 : 460-8.
PubMed
5) Merli F, Luminari S, Rossi G, et al. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma : results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma. 2012 ; 53 : 581-8.
PubMed
6) Merli F, Luminari S, Rossi G, et al. Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment : results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma. 2014 ; 55 : 38-43.
PubMed
7) Extermann M, Hurria A : Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007 ; 25 : 1824-31.
 
8) Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients : a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010 ; 116 : 2040-5.
 
9) Wildiers H, Heeren P, Puts M, et al. International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol. 2014 ; 32 : 2595-603.
 
10) Kasahara S, Hara T, Tsurumi H, et al. Phase II study of the tetrahydropyranyl adriamycin-cyclophosphamide, vincristine, and prednisolone regimen combined with rituximab as first-line treatment for elderly patients with diffuse large B-cell lymphoma. Leuk Lymphoma. 2011 ; 52 : 629-34.
PubMed
11) Miura K, Konishi J, Miyake T, et al. A host-dependent prognostic model for elderly patients with diffuse large B-cell lymphoma. Oncologist. 2017 ; 22 : 554-60.
PubMed
P.305 掲載の参考文献
1) Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma : Societe Francaise de Greffe de Moelle Osseuse-Therapie Cellulaire. J Clin Oncol. 2008 ; 26 : 2512-8.
PubMed
2) Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 ; 125 : 1403-10.
PubMed
3) Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma : results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 ; 4 : e510-23.
 
4) Illerhaus G, Kasenda B, Ihorst G, et al. High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma : a prospective, single-arm, phase 2 trial. Lancet Haematol. 2016 ; 3 : e388-97.
PubMed
5) Soussain C, Choquet S, Fourme E, et al. Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma : a retrospective study of 79 cases. Haematologica. 2012 ; 97 : 1751-6.
 
6) Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years : a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 ; 38 : 417-20.
 
P.309 掲載の参考文献
1) Leoncini L, Campo E, Stein H et al. Burkitt lymphoma. In : Swerdlow SH, et al. editors. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. Lyon, IARC ; 2017. p.330-4.
 
2) 日本血液学会, 編. 造血器腫瘍診療ガイドライン 2018年版. 東京 : 金原出版 ; 2018.
 
3) Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al. An EBMT registry matched study of allogeneic stem cell transplants for lymphoma : allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant. 2003 ; 31 : 667-78.
PubMed
4) Maramattom LV, Hari PN, Burns LJ, et al. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilizalion : A report from the center for International Blood and Marrow Tansplant Research. Biol Blood Marrow Transplant. 2013 ; 19 : 173-9.
 
5) Magrath I, Adde M, Shad A, et al. Adult and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996 ; 14 : 925-34.
PubMed
6) Barnes JA, LaCasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma : a retrospective analysis. Ann Oncol. 2011 ; 22 : 1859-64.
PubMed
7) Thomas DA, Faderi S, O'Brien S, et al. Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic Leukemia. Cancer. 2006 ; 106 : 1569-80.
PubMed
8) Thomas DA, Cortes J, O'Brien S, et al. Hyper-CVAD Program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol. 1999 ; 17 : 2461-70.
 
9) Dunleavy K, Pittaluga S, Shovlin M, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013 ; 369 : 1915-25.
PubMed
10) Rizzieri DA, Johnson JL, Byrd JC, et al. Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas : cancer and Leukemia Group B study 10 002. Br J Haematol. 2014 ; 165 : 102-11.
PubMed
11) LaCasce A, Howard O, Li S, et al. Modified magrath regimens for Adults with Burkitt and Burkitt-like lymphomas : preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004 ; 45 : 761-7.
 
12) Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorublcin, and methotrexate (CODOX-M) /ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma unclassiliable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010 ; 92 : 732-43.
PubMed
P.318 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon : IARC ; 2008.
 
2) Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon : IARC ; 2017.
 
3) Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 ; 30 : 3460-7.
 
4) Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012 ; 30 : 3452-9.
PubMed
5) Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group. J Clin Oncol. 2017 ; 35 : 2515-26.
 
6) Aukema SM, Kreuz M, Kohler CW, et al. Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma. Haematologica. 2014 ; 99 : 726-35.
PubMed
7) Uchida A, Isobe Y, Uemura Y, et al. De novo acute lymphoblastic leukemia-like disease of high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements : a case report and literature review. BMC Clinical Pathol. 2017 ; 17 : 21.
PubMed
8) Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations : the critical factors associated with survival. Blood. 2009 ; 114 : 2273-9.
PubMed
9) Petrich AM, Gandhi M, Jovanovic B et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma : a multicenter retrospective analysis. Blood. 2014 ; 124 : 2354-61.
PubMed
10) Howlett C, Snedecor SJ, Landsburg DJ, et al. Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas : a systematic review and meta-analysis. Br J Haematol. 2015 ; 170 : 504-14.
PubMed
11) Landsburg DJ, Falkiewicz MK, Maly J, et al. Outcomes of patients with double-hit lymphoma who achieve first complete remission. J Clin Oncol. 2017 ; 35 : 2260-7.
PubMed
12) Herrera AF, Mei M, Low L, et al. Relapsed or refractory double-expressor and double-hit lymphomas have inferior progression-free survival after autologous stem-cell transplantation. J Clin Oncol. 2017 ; 35 : 24-31.
PubMed
13) Herrera AF, Rodig SJ, Song JY, et al. Outcomes after allogeneic stem cell transplantation in patients with double-hit and double-expressor lymphoma. Biol Blood Marrow Transplant. 2018 ; 24 : 514-20.
PubMed
P.322 掲載の参考文献
1) Swerdlow SH, Campo E, Harris NL, et al. WHO classfication of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition. Lyon : IARC ; 2017. p.345-422.
 
2) Vose J, Armitage J, Weisenburger D, et al. International peripheral T-cell and natural killer/T-cell lymphoma study : pathology findings and clinical outcomes. J Clin Oncol. 2008 ; 26 : 4124-30.
PubMed
3) Ellin F, Landstrom J, Jerkeman M, et al. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas : a study from the Swedish Lymphoma Registry. Blood. 2014 ; 124 : 1570-7.
PubMed
4) d'Amore F, Relander T, Lauritzsen GF, et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma : NLG-T-01. J Clin Oncol. 2012 ; 30 : 3093-9.
PubMed
P.328 掲載の参考文献
1) Chan JKC, Quintanilla-Martinez L, Ferry JA. Extranodal NK/T-cell lymphoma, nasal type. Swerdlow SH, Campo E, Harris NL, et al (. eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th Edition, Lyon, France : IARC ; 2017. p.368-71.
 
2) Suzuki R, Takeuchi K, Ohshima K, et al. Extranodal NK/T-cell lymphoma : diagnosis and treatment cues. Hematol Oncol. 2008 ; 26 : 66-72.
PubMed
3) Pongpruttipan T, Sukpanichnant S, Assanasen T, et al. Extranodal NK/T-cell lymphoma, nasal type, includes cases of natural killer cell and αβ, γδ, and αβ/γδ T-cell origin : a comprehensive clinicopathologic and phenotypic study. Am J Surg Pathol. 2012 ; 36 : 481-99.
 
4) Yamaguchi M, Kita K, Miwa H, et al. Frequent expression of P-glycoprotein/MDR1 by nasal T-cell lymphoma cells. Cancer. 1995 ; 76 : 2351-6.
PubMed
5) Egashira M, Kawamata N, Sugimoto K, et al. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of P-glycoprotein function by cyclosporin A and its analogue, PSC833. Blood. 1999 ; 93 : 599-606.
PubMed
6) Suzuki R, Suzumiya J, Yamaguchi M, et al. Prognostic factors for mature natural killer (NK) -cell neoplasms : aggressive NK-cell leukemia and extranodal NK-cell lymphoma, nasal-type. Ann Oncol. 2010 ; 21 : 1032-40.
PubMed
7) Yamaguchi M, Tobinai K, Oguchi M, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan Clinical Oncology Group Study JCOG0211. J Clin Oncol. 2009 ; 27 : 5594-600.
 
8) Yamaguchi M, Kwong YL, Kim WS, et al. Phase II study of SMILE chemotherapy for newly-diagnosed stage IV, relapsed or refractory extranodal NK/T-cell lymphoma, nasal type : The NK-cell Tumor Study Group (NKTSG) study. J Clin Oncol. 2011 ; 29 : 4410-6.
PubMed
9) Suzuki R. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia. Int J Hematol. 2010 ; 92 : 697-701.
PubMed
10) Jaccard A, Gachard N, Marin B, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase II study. Blood. 2011 ; 117 : 1834-9.
PubMed
11) Yamaguchi M, Tobinai K, Oguchi M, et al. Concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : an updated analysis of the Japan clinical oncology group study JCOG0211. J Clin Oncol. 2012 ; 30 : 4044-6.
 
12) Yamaguchi M, Suzuki R, Oguchi M, et al. Treatments and outcomes of patients with extranodal natural killer/T-cell lymphoma who were diagnosed between 2000 and 2013 : a cooperative study in Japan. J Clin Oncol. 2017 ; 35 : 32-9.
PubMed
13) Kwong YL, Chan TSY, Tan D, et al. PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase. Blood. 2017 ; 129 : 2437-42.
PubMed
14) Suzuki R. NK/T cell lymphoma : updates in therapy. Curr Hematol Malig Rep. 2018 ; 13 : 7-12.
PubMed
15) Kwong YL, Kim WS, Lim ST, et al. SMILE for natural killer/T-cell lymphoma : analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012 ; 120 : 2973-80.
 
P.333 掲載の参考文献
1) Miura K, Masuzaki H. Prevention of Human T-cell Leukemia Virus Type I (HTLV-1) Mother-to-Child Transmission. In : Watanabe T, Fukushima T, Editors. Adult T-cell Leukemia/Lymphoma. Tokyo : Springer Japan KK ; p.157-69.
 
2) Satake M, Yamaguchi K, Tadokoro K. Current prevalence of HTLV-1 in Japan as determined by screening of blood donors. J Med Virol. 2012 ; 84 : 327-35.
PubMed
3) Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 ; 25 : 5458-64.
 
4) Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia : a nationwide retrospective study. Blood. 2010 ; 116 : 1369-76.
PubMed
5) Ishida T, Jo T, Takemoto S, et al. Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukemia-lymphoma : a randomized phase II study. Br J Haematol. 2015 ; 169 : 672-82.
PubMed
6) Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016 ; 34 : 3426-33.
PubMed
7) Ishida T, Joh T, Yamamoto K, et al. Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma : a multicenter phase II study. J Clin Oncol. 2012 ; 30 : 837-42.
PubMed
8) Ishida T, Fujiwara H, Nosaka K, et al. Multicenter phase II study of lenalidomide in relapsed or recurrent adult T-cell leukemia/lymphoma : ATLL-002. J Clin Oncol. 2016 ; 34 : 4086-93.
PubMed
P.340 掲載の参考文献
1) Uchiyama T, Yodoi J, Sagawa K, et al. Adult T-cell leukemia : clinical and hematologic features of 16 cases. Blood. 1977 ; 50 : 481-92.
PubMed
2) Yoshida M, Seiki M, Yamaguchi K, et al. Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease. Proc Natl Acad Sci U S A. 1984 ; 81 : 2534-7.
PubMed
3) Shimoyama M, Ota K, Kikuchi M, et al. Major prognostic factors of adult patients with advanced T-cell lymphoma/leukemia. J Clin Oncol. 1988 ; 6 : 1088-97.
PubMed
4) Shimoyama M. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol. 1991 ; 79 : 428-37.
 
5) Yamada Y, Tomonaga M, Fukuda H, et al. A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma : Japan Clinical Oncology Group Study 9303. Br J Haematol. 2001 ; 113 : 375-82.
 
6) Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma : Japan Clinical Oncology Group Study JCOG9801. J Clin Oncol. 2007 ; 25 : 5458-64.
 
7) Fukushima T, Nomura S, Shimoyama M, et al. Japan Clinical Oncology Group (JCOG) prognostic index and characterization of long-term survivors of aggressive adult T-cell leukaemia-lymphoma (JCOG0902A). Br J Haematol. 2014 ; 166 : 739-48.
PubMed
8) Katsuya H, Shimokawa M, Ishitsuka K, et al. Prognostic index for chronic- and smoldering-type adult T-cell leukemia-lymphoma. Blood. 2017 ; 130 : 39-47.
PubMed
9) Fuji S, Yamaguchi T, Inoue Y, et al. Development of a modified prognostic index for patients with aggressive adult T-cell leukemia-lymphoma aged 70 years or younger : possible risk-adapted management strategies including allogeneic transplantation. Haematologica. 2017 ; 102 : 1258-65.
PubMed
10) Katsuya H, Yamanaka T, Ishitsuka K, et al. Prognostic index for acute- and lymphoma-type adult T-cell leukemia/lymphoma. J Clin Oncol. 2012 ; 30 : 1635-40.
PubMed
11) Fuji S, Kurosawa S, Inamoto Y, et al. Role of up-front allogeneic hematopoietic stem cell transplantation for patients with aggressive adult T-cell leukemia-lymphoma : a decision analysis. Bone Marrow Transplant. 2018 ; 53 : 905-8.
PubMed
12) Sobue R, Yamauchim T, Miyamura K, et al. Treatment of adult T cell leukemia with mega-dose cyclophosphamide and total body irradiation followed by allogeneic bone marrow transplantation. Bone Marrow Transplant. 1987 ; 2 : 441-4.
PubMed
13) Borg A, Yin JA, Johnson PR, et al. Successful treatment of HTLV-1-associated acute adult T-cell leukaemia lymphoma by allogeneic bone marrow transplantation. Br J Haematol. 1996 ; 94 : 713-5.
PubMed
14) Obama K, Tara M, Sao H, et al. Allogenic bone marrow transplantation as a treatment for adult T-cell leukemia. Int J Hematol. 1999 ; 69 : 203-5.
PubMed
15) Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol. 2000 ; 71 : 290-3.
PubMed
16) Abe Y, Yashiki S, Choi I, et al. Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloablative peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin. Int J Hematol. 2002 ; 76 : 91-3.
 
17) Utsunomiya A, Miyazaki Y, Takatsuka Y, et al. Improved outcome of adult T cell leukemia/lymphoma with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001 ; 27 : 15-20.
PubMed
18) Kami M, Hamaki T, Miyakoshi S, et al. Allogeneic haematopoietic stem cell transplantation for the treatment of adult T-cell leukaemia/lymphoma. Br J Haematol. 2003 ; 120 : 304-9.
PubMed
19) Fukushima T, Miyazaki Y, Honda S, et al. Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia/lymphoma. Leukemia. 2005 ; 19 : 829-34.
 
20) Okamura J, Uike N, Utsunomiya A, et al. Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol. 2007 ; 86 : 118-25.
PubMed
21) Okamura J, Utsunomiya A, Tanosaki R, et al. Allogeneic stem-cell transplantation with reduced conditioning intensity as a novel immunotherapy and antiviral therapy for adult T-cell leukemia/lymphoma. Blood. 2005 ; 105 : 4143-5.
PubMed
22) Choi I, Tanosaki R, Uike N, et al. Long-term outcomes after hematopoietic SCT for adult T-cell leukemia/lymphoma : results of prospective trials. Bone Marrow Transplant. 2011 ; 46 : 116-8.
PubMed
23) Hishizawa M, Kanda J, Utsunomiya A, et al. Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia : a nationwide retrospective study. Blood. 2010 ; 116 : 1369-76.
PubMed
24) Kanda J, Hishizawa M, Utsunomiya A, et al. Impact of graft-versus-host disease on outcomes after allogeneic hematopoietic cell transplantation for adult T-cell leukemia : a retrospective cohort study. Blood. 2012 ; 119 : 2141-8.
PubMed
25) Fukushima T, Itonaga H, Moriuchi Y, et al. Feasibility of cord blood transplantation in chemosensitive adult T-cell leukemia/lymphoma : a retrospective analysis of the Nagasaki Transplantation Network. Int J Hematol. 2013 ; 97 : 485-90.
PubMed
26) Nakamura T, Oku E, Nomura K, et al. Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma : experience at a single institute. Int J Hematol. 2012 ; 96 : 657-63.
 
27) Fuchs EJ. HLA-haploidentical blood or marrow transplantation with high-dose, post-transplantation cyclophosphamide. Bone Marrow Transplant. 2015 ; 50 Suppl 2 : S31-6.
 
28) Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative HLA-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015 ; 33 : 3152-61.
 
29) Fujiwara H, Fuji S, Wake A, et al. Dismal outcome of allogeneic hematopoietic stem cell transplantation for relapsed adult T-cell leukemia/lymphoma, a Japanese nation-wide study. Bone Marrow Transplant. 2017 ; 52 : 484-8.
PubMed
30) Inoue Y, Fuji S, Tanosaki R, et al. Prognostic importance of pretransplant disease status for posttransplant outcomes in patients with adult T cell leukemia/lymphoma. Bone Marrow Transplant, 2018. Epub ahead of print.
 
31) Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016 ; 34 : 3426-33.
PubMed
32) Fuji S, Utsunomiya A, Inoue Y, et al. Outcomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma : clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica. 2018 ; 103 : e211-4.
PubMed
33) Fuji S, Shindo T. Friend or foe? Mogamulizumab in allogeneic hematopoietic stem cell transplantation for adult T-cell leukemia/lymphoma. Stem Cell Investig. 2016 ; 3 : 70.
PubMed
34) Fuji S, Utsunomiya A, Inoue Y, et al. Outocomes of patients with relapsed aggressive adult T-cell leukemia-lymphoma : clinical effectiveness of anti-CCR4 antibody and allogeneic hematopoietic stem cell transplantation. Haematologica. 2018 ; 103 : e211-4.
 
P.348 掲載の参考文献
1) Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease : Cotswolds meeting. J Clin Oncol. 1989 ; 7 : 1630-6.
PubMed
2) Ferme C, Eghbali H, Meerwaldt JH, et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med. 2007 ; 357 : 1916-27.
PubMed
3) Bonadonna G, Bonfante V, Viviani S, et al. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease : long-term results. J Clin Oncol. 2004 ; 22 : 2835-41.
PubMed
4) Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med. 2010 ; 363 : 640-52.
PubMed
5) Eich HT, Diehl V, Gorgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma : final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010 ; 28 : 4199-206.
 
6) Radford J, Illidge T, Counsell N, et al. Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med. 2015 ; 372 : 1598-607.
PubMed
7) Engert A, Schiller P, Josting A, et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma : results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol. 2003 ; 21 : 3601-8.
 
8) Noordijk EM, Carde P, Dupouy N, et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma : long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol. 2006 ; 24 : 3128-35.
PubMed
P.353 掲載の参考文献
1) Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992 ; 327 : 1478-84.
PubMed
2) 日本血液学会, 編. 造血器腫瘍診療ガイドライン. 東京 : 金原出版 ; 2018,
 
3) Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial) : a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012 ; 379 : 1791-99.
 
4) Viviani S, Zinzani PL, Rambaldi A, et al. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med. 2011 ; 365 : 203-12.
PubMed
5) Gallamini A, Hutchings M, Rigacci L, et al. Early interim 2- [18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma : a report from a joint Italian-Danish study. J Clin Oncol. 2007, 25 : 3746-52.
PubMed
6) Press OW, Li H, Schoder H, et al. US Intergroup Trial of Response-adapted therapy for stage III to IV Hodgkin lymphoma using early interim fluorodeoxyglucose-positron emission tomography imaging : Southwest Oncology Group S0816. J Clin Oncol. 2016 ; 34 : 2020-7.
 
7) Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma. N Engl J Med. 2016, 374 : 2419-29.
PubMed
8) Connors JM, Jurczak W, Straus DJ, et al. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma. N Engl J Med. 2018 ; 378 : 331-44.
PubMed
9) Martin WG, Ristow KM, Habermann TM, et al. Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma. J Clin Oncol. 2005 ; 23 :7614-20.
 
10) Evens AM, Helenowski I, Ramsdale E, et al. A retrospective multicenter analysis of elderly Hodgkin lymphoma : outcomes and prognostic factors in the modern era. Blood. 2012 ; 119 : 692-5.
PubMed
P.356 掲載の参考文献
1) Herrera AF, Palmer J, Martin P, et al. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma. Ann Oncol. 2018 ; 29 : 724-30.
PubMed
2) Moskowitz AJ, Schoder H, Yahalom J, et al. PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma : a non-randomised, open-label, single-centre, phase 2 study. Lancet Oncol. 2015 ; 16 : 284-92.
PubMed
3) Armand P, Engert A, Younes A, et al. Nivolumab for Relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation : extended follow-up of the multicohort single-arm phase II CheckMate 205 Trial. J Clin Oncol. 2018 ; 36 : 1428-39.
 
4) Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018 ; 131 : 1183-94.
PubMed
5) Chen R, Zinzani PL, Fanale MA, et al. KEYNOTE-087. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017 ; 35 : 2125-32.
PubMed

V. 多発性骨髄腫と関連疾患

P.363 掲載の参考文献
1) Kyle RA, Greipp PR. Smoldering multiple myeloma. N Engl J Med. 1980 ; 302 : 1347-9.
PubMed
2) Hjorth M, Hellquist L, Holmberg E, et al. Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I ; a randomized study. Myeloma Group of Western Sweden. Eur J Haematol. 1993 ; 50 : 95-102.
 
3) Riccardi A, Mora O, Tinelli C, et al. Long-term survival of stage I multiple myeloma given chemotherapy just after diagnosis or at progression of the disease : a multicentre randomized study. Cooperative Group of Study and Treatment of Multiple Myeloma. Br J Cancer. 2000 ; 82 : 1254-60.
PubMed
4) Kyle RA, Remstein ED, Therneau TM, et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007 ; 356 : 2582-90.
PubMed
5) Mateos MV, Hernandez MT, Giraldo P, et al. Lenalidomide plus dexamethasone for high-risk smoldering multiple myeloma. N Engl J Med. 2013 ; 369 : 438-47.
PubMed
6) Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014 ; 15 : e538-48.
 
7) Korde N, Roschewski M, Zingone A, et al. Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma. JAMA Oncol. 2015 ; 1 : 746-54.
PubMed
8) Mailankody S, Kazandjian D, Korde N, et al. Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. Blood Adv. 2017 ; 1 : 1911-8.
PubMed
9) Cherry BM, Korde N, Kwok M, et al. Modeling progression risk for smoldering multiple myeloma : results from a prospective clinical study. Leuk Lymphoma. 2013 ; 54 : 2215-8.
PubMed
10) Durie BG, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomised, open-label, phase 3 trial. Lancet. 2017 ; 389 : 519-27.
PubMed
P.369 掲載の参考文献
1) Harousseau JL, Attal M, Avet-Loiseau H, et al. Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma : results of the IFM 2005-01 phase III trial. J Clin Oncol. 2010 ; 28 : 4621-9.
PubMed
2) Sonneveld P, Schmidt-Wolf IG, van der Holt B, et al. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma : results of the randomized phase III HOVON-65/GMMG-HD4 trial. J Clin Oncol. 2012 ; 30 : 2946-55.
 
3) Moreau P, Avet-Loiseau H, Harousseau JL, et al. Current trends in autologous stem-cell transplantation for myeloma in the era of novel therapies. J Clin Oncol. 2011 ; 29 : 1898-906.
PubMed
4) Roussel M, Lauwers-Cances V, Robillard N, et al. Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma : a phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol. 2014 ; 32 : 2712-7.
PubMed
5) Zimmerman T, Raje NS, Vij R, et al. Final Results of a Phase 2 Trial of Extended Treatment (tx) with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (KRd) Plus Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM). Blood. 2016 ; 128 : 675.
 
6) Ri M, Matsue K, Sunami K, et al. Efficacy and safety of plerixafor for the mobilization/collection of peripheral hematopoietic stem cells for autologous transplantation in Japanese patients with multiple myeloma. Int J Hematol. 2017 ; 106 : 562-72.
PubMed
7) Mohty M, Hubel K, Kroger N, et al. Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients : a position statement from the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2014 ; 49 : 865-72.
 
8) Gay F, Oliva S, Petrucci MT, et al. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma : a randomised, multicentre, phase 3 trial. Lancet Oncol. 2015 ; 16 : 1617-29.
PubMed
9) Oliva S, Bruinink DHo, RIhova L, et al. Minimal residual disease (MRD) monitoring by multiparameter flow cytometry (MFC) in newly diagnosed transplant eligible multiple myeloma (MM) patients : Results from the EMN02/HO95 phase 3 trial. J Clin Oncol. 2017 ; 35 (15_suppl) : 8011.
 
10) Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 ; 376 : 1311-20.
PubMed
11) Bayraktar UD, Bashir Q, Qazilbash M, et al. Ciurea SO. Fifty years of melphalan use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplantat. 2013 ; 19 : 344-56.
 
12) Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J med. 2014 ; 371 : 895-905.
PubMed
13) Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma : a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 ; 4 : e431-e42.
PubMed
14) McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma : A Meta-Analysis. J Clin Oncol. 2017 ; 35 : 3279-89.
PubMed
15) Pulte ED, Dmytrijuk A, Nie L, et al. FDA approval summary : lenalidomide as maintenance therapy after autologous stem cell transplant in newly diagnosed multiple myeloma. Oncologist. 2018. Epub ahead of print.
 
P.374 掲載の参考文献
1) Ozaki S, Handa H, Saitoh T, et al. Trends of survival in patients with multiple myeloma in Japan : a multicenter retrospective collaborative study of the Japanese Society of Myeloma. Blood Cancer J. 2015 ; 5 : e349.
PubMed
2) San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008 ; 359 : 906-17.
PubMed
3) Benboubker L, Dimopoulos MA, Dispenzieri A, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014 ; 371 : 906-17.
PubMed
4) Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777) : a randomized, open-label, phase 3 trial. Lancet. 2017 ; 389 : 519-77.
PubMed
5) Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018 ; 378 : 518-28.
PubMed
6) Attal M, Lauwers-Cances V, Hulin C, et al. Lenaidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017 ; 376 : 1311-20.
PubMed
P.379 掲載の参考文献
1) Rajkumar SV, Harousseau JL, Durie B, et al. Consensus recommendations for the uniform reporting of clinical trials : report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 ; 117 : 4691-5.
PubMed
2) De Larrea CF, Jimenez R, Rosinol L, et al. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant. 2014 ; 49 : 223-7.
 
3) Botta C, Ciliberto D, Rossi M, et al. Network meta-analysis of randomized trials in multiple myeloma : efficacy and safety in relapsed/refractory patients. Blood Adv. 2017 ; 1 : 455-66.
PubMed
4) Van Beurden-Tan CHY, Franken MG, Blommenstein HM, et al. Systemic literature review and network meta-analysis of treatment outcomes in relapsed and/or refractory multiple myeloma. J Clin Oncol. 2017 ; 35 : 1312-9.
PubMed
5) Chim CS, Kumar SK, Orlowski RZ, et al. Management of relapsed and refractory multiple myeloma : novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018 ; 32 : 252-62.
PubMed
6) Sonneveld P. Management of multiple myeloma in the relapsed/refractory patient. Hematology. 2017 ; 508-17.
PubMed
P.383 掲載の参考文献
1) Gay F, Engelhardt M, Terpos E, et al. From transplant to novel cellular therapies in multiple myeloma : European Myeloma Network guidelines and future perspectives. Haematologica. 2018 ; 103 : 197-211.
PubMed
2) McCarthy PL, Holstein SA, Petrucci MT, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma : a meta-analysis. J Clin Oncol. 2017 ; 35 : 3279-89.
PubMed
3) Goldschmidt H, Lokhorst HM, Mai EK, et al. Bortezomib before and after high-dose therapy in myeloma : long-term results from the phase III HOVON-65/GMMG-HD4 trial. Leukemia. 2018 ; 32 : 383-90.
PubMed
4) Morgan GJ, Gregory WM, Davies FE, et al. The role of maintenance thalidomide therapy in multiple myeloma : MRC myeloma IX results and meta-analysis. Blood. 2012 ; 119 : 7-15.
PubMed
5) Palumbo A, Gay F, Cavallo F, et al. Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma. J Clin Oncol. 2015 ; 33 : 3459-66.
PubMed
6) Mellqvist UH, Gimsing P, Hjertner O, et al. Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma : a Nordic Myeloma Study Group randomized phase 3 trial. Blood. 2013 ; 121 : 4647-54.
 
7) Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 2012 ; 366 : 1759-69.
PubMed
8) Holstein SA, Jung SH, Richardson PG, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma : a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 ; 4 : e431-e42.
PubMed
9) Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 ; 366 : 1782-91.
PubMed
10) McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012 ; 366 : 1770-81.
PubMed
11) Cerrato C, Di Raimondo F, De Paoli L, et al. Maintenance in myeloma patients achieving complete response after upfront therapy : a pooled analysis. J Cancer Res Clin Oncol. 2018 ; 144 : 1357-66.
PubMed
12) Mina R, Petrucci MT, Corradini P, et al. Treatment intensification with autologous stem cell transplantation and lenalidomide maintenance improves survival outcomes of patients with newly diagnosed multiple myeloma in complete response. Clin Lymphoma Myeloma Leuk. 2018 ; 18 : 533-540.
PubMed
P.388 掲載の参考文献
1) Augeul-Meunier K, Chretien M-L, Stoppa A-M, et al. Extending autologous transplantation as first line therapy in multiple myeloma patients with severe renal impairment : a retrospective study by the SFGM-TC. Bone Marrow Transplantation. 2018 Mar 9. doi : 10.1038/s41409-018-0122-8. [Epub ahead of print]
 
2) Steiner N, Gobel G, Suchecki P, et al. Monoclonal gammnopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma : an observational study of 2935 MGUS patients. Oncotarget. 2018 ; 9 : 2344-2356.
PubMed
3) Takeuchi K, Abe M, Hiasa M, et al. TGF-β inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One. 2010 ; 5 : e9870
 
4) Dimopoulos MA, Sonneveld P, Leung N, et al. International Myeloma Working Group Recommendations for the diagnosis and management of myeloma-related renal impairment. J Clin Oncol. 2016 ; 34 : 1544-57.
 
5) Terpos E, Kleber M, Engelhardt M, et al. European Myeloma Network Guidelines for the Management of myeloma-related complications. Haematologica. 2015 ; 100 : 1254-66.
PubMed
6) Raje N, Terpos E, Willenbacher W, et al. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma : an international, double-blind, double-dummy, randomized, controlled, phase 3 study. Lancet Oncol. 2018 ; 19 : 370-81.
 
7) Anderson K, Ismaila N, Flynn PJ, et al. Role of bone-modifying agents in multiple myeloma : American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2018 ; 36 : 812-8.
 
8) Teh BW, Harrison SJ, Slavin MA, et al. Epidemiology of blood stream infections in patients with myeloma receiving current era therapy. Eur J Haematol. 2017 ; 98 : 149-53.
 
9) Konig C, Kleber M, Reinhardt H, et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Haematol. 2014 ; 93 : 479-84.
 
P.394 掲載の参考文献
1) Fernandez de Larrea C, Kyle RA, Durie BG, et al. Plasma cell leukemia : consensus statement on diagnostic requirements, response criteria and treatment recommendations by the international myeloma working group. Leukemia. 2013 ; 27 : 780-91.
 
2) Gonsalves WI, Rajkumar V, Go RS, et al. Trends in survival of patients with primary plasma cell leukemia : a population-based analysis. Blood. 2014 ; 124 : 907-12.
 
3) Noel P, Kyle RA. Plasma cell leukemia : an evaluation of response to therapy. Am J Med. 1987 ; 83 : 1062-8.
PubMed
4) Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary leukemia : results from the Center for International Blood and Marrow Transplant Research. Leukemia. 2012 ; 26 : 1091-7.
 
5) Royer B, Minvielle S, Diouf M, et al. Bortezomib, doxorubicin, cyclophosphamide, dexamethasone induction followed by stem cell transplantation for primary plasma cell leukemia : a prospective phase II study of the Intergroupe Francophone du Myelome. J Clin Oncol. 2016 ; 34 : 2125-32.
PubMed
6) Iriuchisima H, Ozaki S, Konishi J, et al. Primary plasma cell leukemia in the era of novel agents : a multicenter study of the Japanese Society of Myeloma. Acta Haematol. 2016 ; 135 : 113-21.
 
7) Katodritou E, Terpos E, Delimpasi S, et al. Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents : a ulticenter national study by the Greek Myeloma Study Group. Blood Cancer Journal. 2018 ; 8 : 31.
 
P.400 掲載の参考文献
1) Swerdlow SH, Cook JR, Sohani AR, et al. Lymphoplastic lymphoma. In : Swerdlow SH, et al (eds), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. IARC Press. 2017. p.195-232.
 
2) Gertz MA. Waldenstrom macroglobulinemia : 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2017 ; 92 : 209-17.
 
3) Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia : Final analysis of a phase 2 study. Blood. 2015 ; 126 : 1392-4.
PubMed
4) Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007 ; 25 : 3344-9.
PubMed
5) Gavriatopoulou M, Garcia-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM : final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 ; 129 : 456-9.
PubMed
6) Dimopoulos MA, Garcia-Sanz R, Gavriatopoulou M, et al. Primary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR) : long-term results of a phase 2 study of the European Myeloma Network (EMN). Blood. 2013 ; 122 : 3276-82.
PubMed
7) Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas : an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013 ; 381 : 1203-10.
PubMed
8) Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenstrom macroglobulinemia. Ann Hematol. 2018 ; 97 : 1417-25.
PubMed
9) Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenstrom's macro globulinaemia (iNNOVATE) : an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 ; 18 : 241-50.
 
10) Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia : the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010 ; 28 : 2227-32.
 
P.405 掲載の参考文献
1) Palladini G, Perfetti V, Obici L, et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood. 2004 ; 103 : 2936-8.
PubMed
2) Jaccard A, Moreau P, Leblond V, et al. High-dose melphalan plus dexamethasone for AL amyloidosis. N Engl J Med. 2007 ; 357 : 1083-93.
PubMed
3) Palladini G, Milani P, Foli A, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis : long-term esults of risk-adapted approach. Haematologica. 2014 ; 99 : 743-50.
 
4) D'Souza A, Dispenzieri A, Wirk B, et al. Improved outcomes after autologous hematopoietic cell transplantation for light chain amyloidosis : A center for International Blood and Marrow Transplant Research Study. J Clin Oncol. 2015 ; 33 : 3741-9.
PubMed
5) Sidiqi MH, Aljama MA, Buadi FK, et al. Stem cell transplantation for light chain amyloidosis : Decreased early mortality over time. J Clin Oncol. 2018 ; 36 : 1323-9.
PubMed
6) Palladini G, Sachchithanantham S, Milani P, et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood. 2015 ; 126 : 612-5.
 
7) Dietrich S, Schonland SO, Benner A, et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood. 2010 ; 116 : 522-8.
 
P.410 掲載の参考文献
1) Castleman B, Towne VW. CASE records of the Massachusetts General Hospital Weekly Clinicopathological Exercises : Case 40011. N Engl J Med. 1954 ; 250 : 26-30.
 
2) Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956 ; 9 : 822-30.
PubMed
3) Keller AR, Hochholzer L, Castleman B. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer. 1972 ; 29 : 670-83.
PubMed
4) 吉崎和幸, 岡本真一郎, 川端浩, 他. キャッスルマン病診療の参照ガイド. 臨床血液. 2017 ; 58 : 97-107.
 
5) Bartoli E, Massarelli G, Soggia G, et al. Multicentric giant lymph node hyperplasia. A hyperimmune syndrome with a rapidly progressive course. Am J Clin Pathol. 1980 ; 73 : 423-6.
PubMed
6) Gaba AR, Stein RS, Sweet DL, et al. Multicentric giant lymph node hyperplasia. Am J Clin Pathol. 1978 ; 69 : 86-90.
PubMed
7) Frizzera G, Banks PM, Massarelli G, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease. Pathological findings in 15 patients. Am J Surg Pathol. 1983 ; 7 : 211-31.
PubMed
8) Soulier J, Grollet L, Oksenhendler E, et al. Kaposis's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995 ; 86 : 1276-80.
PubMed
9) Cronin DM, Warnke RA. Castleman disease : an update on classification and the spectrum of associated lesions. Adv Anat Pathol. 2009 ; 16 : 236-46.
PubMed
10) Kawabata H, Kadowaki N, Nishikori M, et al. Clinical features and treatment of multicentric Castleman's disease : a retrospective study of 21 Japanese patients at a single institute. J Clin Exp Hematop. 2013 ; 53 : 69-77.
 
11) Talat N, Belgaumkar AP, Schulte KM. Surgery in Castleman's disease : a systematic review of 404 published cases. Ann Surg. 2012 ; 255 : 677-84.
PubMed
12) Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005 ; 106 : 2627-32.
PubMed
13) van Rhee F, Wong RS, Munshi N, et al. Siltuximab for multicentric Castleman's disease : a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014 ; 15 : 966-74.
PubMed
14) Ide M, Kawachi Y, Izumi Y, et al. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab. Eur J Haematol. 2006 ; 76 : 119-23.
PubMed
P.415 掲載の参考文献
1) Dispenzieri A. POEMS syndrome : 2017 Update on diagnosis, risk stratification, and management. Am J Hematol. 2017 ; 92 : 814-29.
PubMed
2) Watanabe O, Arimura K, Kitajima I, et al. Greatly raised vascular endothelial growth factor (VEGF) in POEMS syndrome. Lancet. 1996 ; 347 : 702.
PubMed
3) Misawa S, Sato Y, Katayama K, et al. Safety and efficacy of thalidomide in patients with POEMS syndrome : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016 ; 15 : 1129-37.
PubMed
4) Ohwada C, Sakaida E, Kawajiri-Manako C, et al. Long-term evaluation of physical improvement and survival of autologous stem cell transplantation in POEMS syndrome. Blood. 2018 ; 131 : 2173-6.
PubMed
5) Li J, Huang XF, Cai QQ, et al. A prospective phase II study of low dose lenalidomide plus dexamethasone in patients with newly diagnosed polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome. Am J Hematol. 2018 ; 93 : 803-9.
 
6) Kawajiri-Manako C, Sakaida E, Ohwada C, et al. Efficacy and long-term outcomes of autologous stem cell transplantation in POEMS Syndrome : A Nationwide Survey in Japan. Biol Blood Marrow Transplant. 2018 ; 24 : 1180-6.
PubMed
7) D'Souza A, Lacy M, Gertz M, et al. Long-term outcomes after autologous stem cell transplantation for patients with POEMS syndrome (osteosclerotic myeloma) : a single-center experience. Blood. 2012 ; 120 : 56-62.
PubMed
8) Dispenzieri A, Lacy MQ, Hayman SR, et al. Peripheral blood stem cell transplant for POEMS syndrome is associated with high rates of engraftment syndrome. Eur J Haematol. 2008 ; 80 : 397-406.
PubMed
P.421 掲載の参考文献
1) 高井和江, 新國広司, 渋谷宏行, 他. 発熱, 胸腹水, 肝脾腫を伴い, 骨髄に軽度の繊維化を認める血小板減少症. 臨床血液. 2010 ; 51 : 320-5.
 
2) Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease : novel insights into biology, pathogenesis, and therapy. Blood. 2014 ; 123 : 2924-33.
PubMed
3) Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric. Pathol Int. 2001 ; 51 : 671-79.
PubMed
4) Liu AY, Nabel CS, Finkelman BS, et al. Idiopathic multicentric Castleman's disease : a systematic literature review. Lancet Haematol. 2016 ; 3 : e163-75.
PubMed
5) Iwaki N, Fajgenbaum DC, Nabel CS, et al. Clinicopathologic analysis of TAFRO syndrome demonstrates a distinct subtype of HHV-8-negative multicentric Castleman disease. Am J Hematol. 2016 ; 91 : 220-6.
PubMed
6) Masaki Y, Kawabata H, Takai K, et al. Proposed diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, 2015 version. Int J Hematol. 2016 ; 103 : 686-92.
PubMed

VI. 出血・血栓性疾患

P.428 掲載の参考文献
1) 藤村欣吾, 宮川義隆, 倉田義之, 他. 成人特発性血小板減少性紫斑病治療の参照ガイド 2012年版. 臨血. 2012 ; 53 : 433-42.
 
2) Kashiwagi H, Tomiyama Y. Pathophysiology and management of primary immune thrombocytopenia. Int J Hematol. 2013 ; 98 : 24-33.
PubMed
3) 冨山佳昭. ITPにおけるTPO受容体作動薬の使い方. In : 高久史麿, 小澤敬也, 坂田洋一, 他, 編, Annual Review 血液 2012. 東京 ; 中外医学社 ; 2012. p.198-206.
 
4) Vianelli N, Palandri F, Polverelli N, et al. Splenectomy as a curative treatment for immune thrombocytopenia : a retrospective analysis of 233 patients with a minimum follow up of 10 years. Haematologica. 2013 ; 98 : 875-80.
PubMed
5) Wong RSM, Saleh MN, Khelif A, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag : final results of the EXTEND study. Blood. 2017 ; 130 : 2527-36.
PubMed
6) Marangon M, Vianelli N, Palandri F, et al. Rituximab in immune thrombocytopenia : gender, age, and response as predictors of long-term response. Eur J Haematol. 2017 ; 98 : 371-7.
PubMed
7) Kuter DJ, Bussel JB, Newland A, et al. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia : safety and efficacy. Br J Haematol. 2013 ; 161 : 411-23.
PubMed
8) Ghanima W, Khelif A, Waage A, et al. Rituximab as second-line treatment for adult immune thrombocytopenia (the RITP trial) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015 ; 385 : 1653-61.
 
P.435 掲載の参考文献
1) EL A, JE U. Thrombotic thrombocytopenic purpura : report of 16 cases and review of the literatire. Medicine. 1966. p.139-59.
 
2) Rock GA, Shumak KH, Buskard NA, et al. Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med. 1991 ; 325 : 393-7.
 
3) 難治性疾患等政策研究事業「血液凝固異常症に関する調査研究班」TTPグループ, 松本雅則, 藤村吉博, 和田英夫, 他. 血栓性血小板減少性紫斑病 (TTP) 診療ガイド 2017. 臨床血液. 2017 ; 58 : 271-81.
 
4) Isonishi A, Bennett CL, Plaimauer B, et al. Poor responder to plasma exchange therapy in acquired thrombotic thrombocytopenic purpura is associated with ADAMTS13 inhibitor boosting : visualization of an ADAMTS13 inhibitor complex and its proteolytic clearance from plasma. Transfusion. 2015 ; 55 : 2321-30.
PubMed
5) Lim W, Vesely SK, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015 ; 125 : 1526-31.
PubMed
6) Miyakawa Y, Imada K, Ichinohe T, et al. Efficacy and safety of rituximab in Japanese patients with acquired thrombotic thrombocytopenic purpura refractory to conventional therapy. Int J Hematol. 2016 ; 104 : 228-35.
PubMed
7) Peyvandi F, Scully M, Kremer Hovinga JA, et al. Caplacizumab for acquired thrombotic thrombocytopenic purpura. N Engl J Med. 2016 ; 374 : 511-22.
PubMed
P.439 掲載の参考文献
1) 日本腎臓学会, 日本小児科学会. 非典型溶血性尿毒症症候群 (aHUS) 診療ガイド 2015.
 
2) Fujisawa M, Kato H, Yoshida Y, et al. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol. 2018 in press.
 
3) Yoshida Y, Miyata T, Matsumoto M, et al. A novel quantitative hemolytic assay coupled with restriction fragment length polymorphisms analysis enabled early diagnosis of atypical hemolytic uremic syndrome and identified unique predisposing mutations in Japan. PLoS One. 2015 ; 10 : e0124655.
 
4) Hourmant M, Cataland SR, Espinosa M, et al. Eculizumab (ECU) inhibits thrombotic microangiopathy (TMA) and improves renal function in adult patients (Pts) with atypical hemolytic uremic syndrome (aHUS). Blood. 2013 ; 122 : 2179.
 
5) Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013 ; 368 : 2169-81.
PubMed
6) McNamara LA, Topaz N, Wang X, et al. High risk for invasive meningococcal disease among patients receiving eculizumab (Soliris) despite receipt of meningococcal vaccine. Am J Transplant. 2017 ; 17 : 2481-4.
 
7) Fakhouri F, Fila M, Provot F, et al. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017 ; 12 : 50-9.
PubMed
8) Ardissino G, Possenti I, Tel F, et al. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome : an update. Am J Kidney Dis. 2015 ; 66 : 172-3.
PubMed
P.444 掲載の参考文献
1) Di Michele DM. Immune tolerance induction in haemophilia : evidence and the way forward. J Thromb Haemost. 2011 ; 9 Suppl 1 : 216-25.
 
2) Coyle TE, Reding MT, Lin JC, et al. Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A. J Thromb Haemost. 2014 ; 12 : 488-96.
PubMed
3) Escuriola Ettingshausen C HI, Simpson M, et al. A head-to-head pharmacokinetic comparison of N9-GP and rFIXFc in patients with haemophilia B. Presented at the WFH 2018 World Congress, Glasgow, UK ; 2018.
 
4) Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med. 2015 ; 21 : 492-7.
PubMed
5) Hilden I, Lauritzen B, Sorensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012 ; 119 : 5871-8.
 
6) Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006 ; 12 : 342-7.
PubMed
7) Jiang H, Lillicrap D, Patarroyo-White S, et al. Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood. 2006 ; 108 : 107-15.
PubMed
8) Mcintosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood. 2013 ; 121 : 3335-44.
PubMed
9) Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med. 2014 ; 371 : 1994-2004.
PubMed
10) Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. N Engl J Med. 2017 ; 377 : 2519-30.
PubMed
11) George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017 ; 377 : 2215-27.
PubMed
12) Wang C, Young G. Clinical use of recombinant factor VIII Fc and recombinant factor IX Fc in patients with haemophilia A and B. Haemophilia 2018 ; (https://doi.org/10.1111/hae.13432)
 
13) Mahlangu J, Young G, Hermans C, et al. Defining extended half-life rFVIII-A critical review of the evidence. Haemophilia. 2018 ; (https://doi.org/10.1111/hae.13438)
 
14) Shima M, Hanabusa H, Taki M, et al. Long-term safety and efficacy of emicizumab in a phase 1/2 study in patients with hemophilia A with or without inhibitors. Blood Adv. 2017 ; 1 : 1891-9.
PubMed
15) 日本血栓止血学会. インヒビター保有先天性血友病患者に対する止血治療ガイドライン 2013年改訂版. 日本血栓止血学会. 2013.
 
P.449 掲載の参考文献
1) Collins PW, Hirsch S, Baglin TP, et al. Acquired hemophilia A in the United Kingdom : a 2-year national surveillance study by the United Kingdom Haemophilia Centre Doctors' Organisation. Blood. 2007 ; 109 : 1870-7.
PubMed
2) 酒井道, 天野景, 小川孔, et al. 後天性血友病A 診療ガイドライン 2017年改訂版. 日本血栓止血学会誌. 2017 ; 28 : 715-47.
 
3) Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). J Thromb Haemost. 2012 ; 10 : 622-31.
PubMed
4) Baudo F, Collins P, Huth-Kuhne A, et al. Management of bleeding in acquired hemophilia A : results from the European Acquired Haemophilia (EACH2) Registry. Blood. 2012 ; 120 : 39-46.
 
5) Amano K, Seita I, Higasa S, et al. Treatment of acute bleeding in acquired haemophilia A with recombinant activated factor VII : analysis of 10-year Japanese postmarketing surveillance data. Haemophilia. 2017 ; 23 : 50-8.
PubMed
6) Collins P, Baudo F, Knoebl P, et al. Immunosuppression for acquired hemophilia A : results from the European Acquired Haemophilia Registry (EACH2). Blood. 2012 ; 120 : 47-55.
PubMed
7) Shinkoda Y, Shirahata A, Fukutake K, et al. A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors. Haemophilia. 2017 ; 23 : 59-66.
PubMed
8) Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to Factor VIII. Thromb Haemost. 1981 ; 45 : 200-3.
PubMed
9) Delgado J, Jimenez-Yuste V, Hernandez-Navarro F, et al. Acquired haemophilia : review and meta-analysis focused on therapy and prognostic factors. Br J Haematol. 2003 ; 121 : 21-35.
 
P.454 掲載の参考文献
1) DIC診断基準作成委員会. 日本血栓止血学会DIC診断基準 2017年版. 血栓止血誌. 2017 ; 28 : 369-91.
 
2) Asakura H, Takahashi H, Uchiyama T, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016 ; 14 : 42.
PubMed
3) Wada H, Takahashi H, Uchiyama T, et al. The approval of revised diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2017 ; 15 : 17.
PubMed
4) Aota T, Wada H, Fujimoto N, et al. Evaluation of the diagnostic criteria for the basic type of DIC established by the Japanese Society of Thrombosis and Hemostasis. Clin Appl Thromb Hemost. 2017 ; 23 : 838-43.
PubMed
5) Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013 ; 17 : R297.
PubMed
6) Iba T, Gando S, Saitoh D, et al. Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation. Thromb Res. 2016 ; 145 : 46-50.
PubMed
7) Yoshimura J, Yamakawa K, Ogura H, et al. Benefit profile of recombinant human soluble thrombomodulin in sepsis-induced disseminated intravascular coagulation : a multicenter propensity score analysis. Crit Care. 2015 ; 19 : 78.
 
8) Saito H, Maruyama I, Shimazaki S, et al. Efficacy and safety of recombinant human soluble thrombomodulin (ART-12) in disseminated intravascular coagulation : results of a phase III, randomized, double-blind clinical trial. J Thromb Haemost. 2007 ; 5 : 31-41.
 
9) Wada H, Okamoto K, Iba T, et al. Addition of recommendations for the use of recombinant human thrombomodulin to the "Expert consensus for the treatment of disseminated intravascular coagulation in Japan". Thromb Res. 2014 ; 134 : 924-5.
 
10) Avvisati G, ten Cate JW, Buller HR, et al. Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. Lancet. 1989 ; 2 : 122-4.
PubMed
11) Gayet-Ageron A, Prieto-Merino D, Ker K, et al. Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage : a meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet. 2018 ; 391 : 125-32.
PubMed
12) Bell SF, Rayment R, Collins PW, et al. The use of fibrinogen concentrate to correct hypofibrinogenaemia rapidly during obstetric haemorrhage. Int J Obstet Anesth. 2010 ; 19 : 218-23.
 
13) Wada H, Thachil J, Di Nisio M, et al. Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. J Thromb Haemost. 2013 ; 11 : 761-7.
 
14) Iba T, Di Nisio M, Thachil J, et al. Revision of the Japanese Association for Acute Medicine (JAAM) disseminated intravascular coagulation (DIC) diagnostic criteria using antithrombin activity. Crit Care. 2016 ; 20 : 287.
PubMed
15) Umemura Y, Yamakawa K, Kiguchi T, et al. Design and evaluation of new unified criteria for disseminated intravascular coagulation based on the Japanese Association for Acute Medicine Criteria. Clin Appl Thromb Hemost. 2016 ; 22 : 153-60.
PubMed

VII. 支持療法・輸血

P.462 掲載の参考文献
1) Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database Syst Rev. 2016 ; 10 : CD002042.
PubMed
2) Gu Y, Estcourt LJ, Doree C, et al. Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev 2015 : CD011577.
 
3) 日本輸血・細胞治療学会. 科学的根拠に基づいた赤血球製剤の使用ガイドライン. 日本輸血細胞治療学会誌. 2016 ; 62 : 641-50.
Medical*Online
4) Klein HG, Spahn DR, Carson JL. Red blood cell transfusion in clinical practice. Lancet. 2007 ; 370 : 415-26.
PubMed
5) Weiskopf RB, Viele MK, Feiner J, et al. Human cardiovascular and metabolic response to acute, severe isovolemic anemia. JAMA. 1998 ; 279 : 217-21.
PubMed
6) Carson JL, Guyatt G, Heddle NM, et al. Clinical Practice Guidelines From the AABB : Red Blood Cell Transfusion Thresholds and Storage. JAMA. 2016 ; 316 : 2025-35.
PubMed
7) Remy KE, Hall MW, Cholette J, et al. Mechanisms of red blood cell transfusion-related immunomodulation. Transfusion. 2018 ; 58 : 804-15.
PubMed
8) Hebert PC, Wells G, Blajchman MA, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med. 1999 ; 340 : 409-17.
 
9) Jansen AJ, Caljouw MA, Hop WC, et al. Feasibility of a restrictive red-cell transfusion policy for patients treated with intensive chemotherapy for acute myeloid leukaemia. Transfus Med. 2004 ; 14 : 33-8.
PubMed
10) Webert KE, Cook RJ, Couban S, et al. A multicenter pilot-randomized controlled trial of the feasibility of an augmented red blood cell transfusion strategy for patients treated with induction chemotherapy for acute leukemia or stem cell transplantation. Transfusion. 2008 ; 48 : 81-91.
 
11) Robitaille N, Lacroix J, Alexandrov L, et al. Excess of veno-occlusive disease in a randomized clinical trial on a higher trigger for red blood cell transfusion after bone marrow transplantation : a canadian blood and marrow transplant group trial. Biol Blood Marrow Transplant. 2013 ; 19 : 468-73.
 
12) DeZern AE, Williams K, Zahurak M, et al. Red blood cell transfusion triggers in acute leukemia : a randomized pilot study. Transfusion. 2016 ; 56 : 1750-7.
PubMed
13) Estcourt LJ, Malouf R, Trivella M, et al. Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support. Cochrane Database Syst Rev. 2017 ; 1 : CD011305.
 
14) Hoeks MPA, Kranenburg FJ, Middelburg RA, et al. Impact of red blood cell transfusion strategies in haemato-oncological patients : a systematic review and meta-analysis. Br J Haematol. 2017 ; 178 : 137-51.
PubMed
15) Vincent JL, Baron JF, Reinhart K, et al. Anemia and blood transfusion in critically ill patients. JAMA. 2002 ; 288 : 1499-507.
PubMed
16) Corwin HL, Gettinger A, Pearl RG, et al. The CRIT Study : Anemia and blood transfusion in the critically ill--current clinical practice in the United States. Crit Care Med. 2004 ; 32 : 39-52.
PubMed
17) Vincent JL, Sakr Y, Sprung C, et al. Are blood transfusions associated with greater mortality rates? Results of the Sepsis Occurrence in Acutely Ill Patients study. Anesthesiology. 2008 ; 108 : 31-9.
PubMed
18) Park DW, Chun BC, Kwon SS, et al. Red blood cell transfusions are associated with lower mortality in patients with severe sepsis and septic shock : a propensity-matched analysis*. Crit Care Med. 2012 ; 40 : 3140-45.
PubMed
19) Murphy GJ, Pike K, Rogers CA, et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med. 2015 ; 372 : 997-1008.
 
20) Bergamin FS, Almeida JP, Landoni G, et al. Liberal versus restrictive transfusion strategy in critically ill oncologic patients : The transfusion requirements in critically ill oncologic patients randomized controlled trial. Crit Care Med. 2017 ; 45 : 766-73.
 
21) Hovaguimian F, Myles PS. Restrictive versus liberal transfusion strategy in the perioperative and acute care settings : A context-specific systematic review and meta-analysis of randomized controlled trials. Anesthesiology. 2016 ; 125 : 46-61.
PubMed
22) Chong MA, Krishnan R, Cheng D, et al. Should transfusion trigger thresholds differ for critical care versus perioperative patients? A meta-analysis of randomized trials. Crit Care Med. 2018 ; 46 : 252-63.
PubMed
P.466 掲載の参考文献
1) 厚生労働省医薬・生活衛生局. 血液製剤の使用指針. 平成29年3月.
 
2) 日本輸血・細胞治療学会. 科学的根拠に基づいた血小板製剤の使用ガイドライン. 日本輸血細胞治療学会誌. 2017 ; 63 : 569-84.
Medical*Online
3) Stanworth SJ, Estcourt LJ, Powter G, et al. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013 ; 368 : 1771-80.
PubMed
4) Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med. 1997 ; 337 : 1870-5.
PubMed
5) Kaufman RM, Djulbegovic B, Gernsheimer T, et al. Platelet transfusion : a clinical practice guideline from the AABB. Ann Intern Med. 2015 ; 162 : 205-13.
PubMed
6) Estcourt LJ, Birchall J, Allard S, et al. Guidelines for the use of platelet transfusions. Br J Haematol. 2017 ; 176 : 365-94.
PubMed
7) Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies : an open-label, multicentre, randomised study. Lancet. 2012 ; 380 : 1309-16.
PubMed
8) Heckman KD, Weiner GJ, Davis CS, et al. Randomized study of prophylactic platelet transfusion threshold during induction therapy for adult acute leukemia : 10,000/microL versus 20,000/microL. J Clin Oncol. 1997 ; 15 : 1143-9.
PubMed
9) Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med. 2010 ; 362 : 600-13.
PubMed
10) Sagmeister M, Oec L, and Gmur J. A restrictive platelet transfusion policy allowing long-term support of outpatients with severe aplastic anemia. Blood. 1999 ; 93 : 3124-6.
PubMed
11) Malouf R, Ashraf A, Hadjinicolaou AV, et al. Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders. Cochrane Database Syst Rev. 2018 ; Issue 5.
PubMed
12) Zeidler K, Arn K, Senn O, et al. Optimal preprocedural platelet transfusion threshold for central venous catheter insertions in patients with thrombocytopenia. Transfusion. 2011 ; 51 : 2269-76.
PubMed
13) van de Weerdt EK, Biemond BJ, Zeerleder SS, et al. Prophylactic platelet transfusion prior to central venous catheter placement in patients with thrombocytopenia : study protocol for a randomised controlled trial. Trials. 2018 ; 19 : 127.
 
14) Estcourt LJ, Malouf R, Doree C, et al. Prophylactic platelet transfusions prior to surgery for people with a low platelet count. Cochrane Database Sst Rev. 2017 ; issue 9.
 
P.472 掲載の参考文献
1) Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango : regulation of mammalian iron metabolism. Cell. 2010 ; 142 : 24-38.
PubMed
2) Ikuta K, Hatayama M, Addo L, et al. Iron overload patients with unknown etiology from national survey in Japan. Int J Hematol. 2017 ; 105 : 353-60.
PubMed
3) Takatoku M, Uchiyama T, Okamoto S, et al. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol. 2007 ; 78 : 487-94.
PubMed
4) 小澤敬也 (研究代表者). 輸血後鉄過剰症の診療ガイド. 厚生労働科学研究費補助金難治性疾患克服研究事業. 特発性造血障害に関する調査研究 (平成20年度). 2008.
 
5) Lyons RM, Marek BJ, Paley C, et al. Relation between chelation and clinical outcomes in lower-risk patients with myelodysplastic syndromes : Registry analysis at 5 years. Leuk Res. 2017 ; 56 : 88-95.
PubMed
6) Musto P, Maurillo L, Simeon V, et al. Iron-chelating therapy with deferasirox in transfusion-dependent, higher risk myelodysplastic syndromes : a retrospective, multicenter study. Br J Haematol. 2017 ; 177 : 741-50.
PubMed
7) Gattermann N, Finelli C, Della Porta M, et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica. 2012 ; 97 : 1364-71.
PubMed
P.477 掲載の参考文献
1) Cornely OA, Arikan-Akdgli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014 ; Suppl 3 : 5-26.
 
2) Kontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011 ; 118 : 1216-24.
 
3) Spellberg B, Walsh TJ, Kontoyiannis DP, et al. Recent advances in the management of mucormycosis : from bench to dedside. Clin Infect Dis. 2009 ; 48 : 1743-51.
PubMed
4) Segal BH. Aspergillosis. N Engl J Med. 2009 ; 360 : 1870-4.
PubMed
5) Chamilos G, Marom EM, Lewis RE, et al. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005 ; 41 : 60-6.
PubMed
6) De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008 ; 46 : 1813-21.
 
7) Wahba H, Truong MT, Lei X, et al. Reversed halo sign in invasive pulmonary fungal infections. Clin Infect Dis. 2008 ; 46 : 1733-7.
PubMed
8) Legouge C, Caillot D, Chretien ML, et al. The reversed halo sign : pathognomonic pattern of pulmonary mucormycosis in leukemic patients with neutropenia? Clin Infect Dis. 2014 ; 58 : 672-8.
PubMed
9) Kimura M, Araoka H, Uchida N, et al. Cunninghamella bertholletiae pneumonia showing reversed halo sign on chest computed tomography scan following cord blood transplantation. Med Mycol. 2012 ; 50 : 412-6.
PubMed
10) Georgiadou SP, Sipsas NV, Marom EM, et al. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis. 2011 ; 52 : 1144-55.
PubMed
11) Chamilos G, Lewis RE, Kontoyiannis DP, et al. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008 ; 47 : 503-9.
PubMed
12) Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis : a review of 929 reported cases. Clin Infect Dis. 2005 ; 41 : 643-53.
 
13) Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study : a randomized, double-blind, placebo-controlled trial. J Antimicrobial Chemother. 2012 ; 67 : 715.
 
14) Kyvernitakis A, Torres HA, Jiang Y, et al. Initial use of combination treatment dose not impact survival of 106 patients with haematologic malignancies and mucormycosis : a propensity score analysis. Clin Microbiol Infect. 2016 ; 811. e1-e8.
 
P.482 掲載の参考文献
1) Conrad A, Le Marechal M, Dupont D, et al. A matched case-control study of toxoplasmosis after allogeneic haematopoietic stem cell transplantation : still a devastating complication. Clin Microbiol Infect. 2016 ; 22 : 636-41.
 
2) Martino R, Bretagne S, Einsele H, et al. Early detection of toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis. 2005 ; 40 : 67-78.
PubMed
3) Schmidt M, Sonneville R, Schnell D, et al. Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care : a multicenter study. Clin Infect Dis. 2013 ; 57 : 1535-41.
PubMed
4) Mendorf A, Klyuchnikov E, Langebrake C, et al. Atovaquone for prophylaxis of toxoplasmosis after allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2015 ; 134 : 146-54.
PubMed
5) Sumi M, Aosai F, Norose K, et al. Acute exacerbation of Toxoplasma gondii infection after hematopoietic stem cell transplantation : five case reports among 279 recipients. Int J Hematol. 2013 ; 98 : 214-22.
PubMed
6) Sumi M, Norose K, Hikosaka K, et al. Clinical characteristics and computed tomography findings of pulmonary toxoplasmosis after hematopoietic stem cell transplantation. Int J Hematol. 2016 ; 104 : 729-40.
PubMed
7) Tateno T, Onozawa M, Hashiguchi J, et al. Disseminated toxoplasmosis after hematopoietic stem cell transplantation showing unusual magnetic resonance images. Transpl Infect Dis. 2017 ; 19. doi : 10.1111/tid.12720.
 
8) 住昌彦, 小林光. トキソプラズマ感染症. In : 宮本敏浩, 他編. 造血細胞移植ガイドライン 造血細胞移植後の感染管理. 第4版. 日本造血細胞移植学会 ; 2017. p.30-9.
 
9) Gajurel K, Dhakal R, Montoya JG. Toxoplasma prophylaxis in haematopoietic cell transplant recipients : a review of the literature and recommendations. Curr Opin Infect Dis. 2015 ; 28 : 283-92.
PubMed
P.486 掲載の参考文献
1) Kato H, Fujita H, Akiyama N, et al. Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. Support Care Cancer. 2018.
 
2) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 update by the infectious diseases society of america. Clin Infect Dis. 2011 ; 52 : e56-93.
 
3) 日本臨床腫瘍学会. 発熱性好中球減少症 (FN) 診療ガイドライン. 改訂第2版. 東京 : 南江堂 ; 2017.
 
4) Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. Clin Infect Dis. 2004 ; 38 : 1724-30.
PubMed
5) Lee A, Mirrett S, Reller LB, et al. Detection of bloodstream infections in adults : how many blood cultures are needed? J Clin Microbiol. 2007 ; 45 : 3546-8.
PubMed
6) Akiyama N, Mitani K, Tanaka Y, et al. Fulminant septicemic syndrome of Bacillus cereus in a leukemic patient. Intern Med. 1997 ; 36 : 221-6.
 
7) Kimura SI, Gomyo A, Hayakawa J, et al. Clinical characteristics and predictive factors for mortality in coryneform bacteria bloodstream infection in hematological patients. J Infect Chemother. 2017 ; 23 : 148-53.
PubMed
8) DesJardin JA, Falagas ME, Ruthazer R, et al. Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer. Ann Intern Med. 1999 ; 131 : 641-7.
PubMed
9) Raad I, Hanna HA, Alakech B, et al. Differential time to positivity : a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med. 2004 ; 140 : 18-25.
PubMed
10) Kimura SI, Gomyo A, Hayakawa J, et al. Clinical significance of repeat blood cultures during febrile neutropenia in adult acute myeloid leukaemia patients undergoing intensive chemotherapy. Infect Dis (Lond). 2017 ; 49 : 748-57.
PubMed
11) Heriot GS, Tam C, Waters MJ. Factors predicting the identification of new organisms in follow-up blood cultures drawn during episodes of neutropenic sepsis. Br J Haematol. 2017.
PubMed
12) Araoka H, Baba M, Kimura M, et al. Clinical characteristics of bacteremia caused by Helicobacter cinaedi and time required for blood cultures to become positive. J Clin Microbiol. 2014 ; 52 : 1519-22.
PubMed
13) Chong YP, Moon SM, Bang KM, et al. Treatment duration for uncomplicated Staphylococcus aureus bacteremia to prevent relapse : analysis of a prospective observational cohort study. Antimicrob Agents Chemother. 2013 ; 57 : 1150-6.
PubMed
14) Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis : 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 ; 62 : e1-50.
 
P.495 掲載の参考文献
1) Rolston KV, Yadegarynia D, Kontoyiannis DP, et al. The spectrum of Gram-positive bloodstream infections in patients with hematologic malignancies, and the in vitro activity of various quinolones against Gram-positive bacteria isolated from cancer patients. Int J Infect Dis. 2006 ; 10 : 223-30.
PubMed
2) Venditti Mario, Falcone Marco, Micozzi Alessandra, et al. Staphylococcus aureus bacteremia in patients with hematologic malignancies : a retrospective case-control study. Haematologica. 2003 ; 88 : 923-30.
PubMed
3) Mihu CN, Schaub J, Kesh S, et al. Risk factors for late Staphylococcus aureus bacteremia after allogeneic hematopoietic stem cell transplantation : a single-institution, nested case-controlled study. Biol Blood Marrow Transpl. 2008 ; 14 : 1429-33.
 
4) Mahajan SN, Shah JN, Hachem R, et al. Characteristics and outcomes of methicillin-resistant staphylococcus aureus bloodstream infections in patients with cancer treated with vancomycin : 9-Year experience at a comprehensive cancer center. Oncologist. 2012 ; 17 : 1329-36.
 
5) Shaw BE, Boswell T, Byrne JL, et al. Clinical impact of MRSA in a stem cell transplant unit : Analysis before, during and after an MRSA outbreak. Bone Marrow Transplant. 2007 ; 39 : 623-9.
 
6) Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer : 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2011 ; 52 : 427-31.
 
7) Samuel SA, Lasky RE, Sahasrabhojane P, et al. Development and validation of a clinical model to predict the presence of B-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients. Clin Infect Dis. 2014 ; 59 : 223-30.
 
8) Spanik S, Trupl J, Kunova A, et al. Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci : Analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis. Scand J Infect Dis. 1997 ; 29 : 245-9.
PubMed
9) Mrazova M, Docze A, Buckova E, et al. Prospective national survey of viridans streptococcal bacteraemia risk factors, antibacterial susceptibility and outcome of 120 episodes. Scand J Infect Dis. 2005 ; 37 : 637-41.
PubMed
10) Kamboj M, Chung D, Seo SK, et al. The Changing Epidemiology of Vancomycin-Resistant Enterococcus (VRE) Bacteremia in Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients. Biol Blood Marrow Transplant. 2010 ; 16 : 1576-81.
PubMed
11) Bossaer John B, Hall Philip D, Garrett-Mayer Elizabeth. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer. 2010 ; 19 : 231-7.
 
12) DiazGranados CA, Zimmer SM, Mitchel K, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections : a meta-analysis. Clin Infect Dis. 2005 ; 41 : 327-33.
 
13) Munita Jose M, Murray Barbara E, Arias Cesar A. Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococci. Int J Antimicrob Agents. 2014 : 387-95.
PubMed
14) Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012. Issue 3. CD001835.
 
15) Bhusal Y, Mihu CN, Tarrand JJ, Incidence of fluoroquinolone-resistant and extended-spectrum beta-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011 ; 57 : 335-8.
 
16) Blennow Ola, Ljungman Per. The challenge of antibiotic resistance in haematology patients. Br J Haematol. 2016 ; 172 : 497-511.
PubMed
17) Kang CI, Chung DR, Ko KS, et al. Risk factors for infection and treatment outcome of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol. 2012 ; 91 : 115-21.
PubMed
18) Ng ES, Liew Y, Earnest A, et al. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma. 2011 ; 52 : 131-3.
 
19) Paltansing Sunita, Vlot Jessica A, Kraakman Margriet EM, et al. Extended-spectrum β-lactamase-producing enterobacteriaceae among travelers from the Netherlands. Emerg Infect Dis. 2013 ; 19 : 1206-13.
 
20) Trecarichi EM, Pagano L, Candoni A, et al. Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies : An Italian multicentre prospective survey. Clin Microbiol Infect. 2015 ; 21 : 337-43.
PubMed
21) Girmenia C, Rossolini GM, Piciocchi A, et al. Infections by carbapenem-resistant Klebsiella pneumoniae in SCT recipients : A nationwide retrospective survey from Italy. Bone Marrow Transplant. 2015 ; 50 : 282-8.
PubMed
22) Almyroudis NG, Fuller A, Jakubowski A, et al. Pre- and post-engraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis. 2005 ; 7 : 11-7.
PubMed
23) Ruhnke M, Arnold R, Gastmeier P. Review Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014 ; 15 : e606-19.
PubMed
24) Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with pseudomonas aeruginosa bacteremia in patients with cancer. Arch Intern Med. 2000 ; 160 : 501.
 
25) Johnson LE, D'Agata EMC, Paterson DL, et al. Pseudomonas aeruginosa bacteremia over a 10-year period : Multidrug resistance and outcomes in transplant recipients. Transpl Infect Dis. 2009 ; 11 : 227-34.
 
26) Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014 ; 58 : 5598-601.
PubMed
27) Safdar A, Rolston KV. Stenotrophomonas maltophilia : changing spectrum of a serious bacterial pathogen in patients with cancer. Clin Infect Dis. 2007 ; 45 : 1602-9.
PubMed
28) Ruhnke M, Arnold R, Gastmeier P. Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. Lancet Oncol. 2014 ; 15 : e606-19.
PubMed
P.502 掲載の参考文献
1) Coiffier B, Altman A, Pui CH, et al. Guidelines for the management of pediatric and adult tumor lysis syndrome : an evidence-based review. J Clin Oncol. 2008 ; 26 : 2767-78.
PubMed
2) Cairo MS, Coiffier B, Reiter A, et al. Recommendations for the evaluation of risk and prophylaxis of tumour lysis syndrome (TLS) in adults and children with malignant diseases : an expert TLS panel consensus. Br J Haematol. 2010 ; 149 : 578-86.
PubMed
3) 日本臨床腫瘍学会, 編. 腫瘍崩壊症候群 (TLS) 診療ガイダンス. 東京 : 金原出版 ; 2013.
 
4) Jones GL, Will A, Jackson GH, et al. Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. Br J Haematol. 2015 ; 169 : 661-71.
 
5) Cortes J, Moore JO, Maziarz RT, et al. Control of plasma uric acid in adults at risk for tumor Lysis syndrome : efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. J Clin Oncol. 2010 ; 28 : 4207-13.
PubMed
6) Jeha S, Kantarjian H, Irwin D, et al. Efficacy and safety of rasburicase, a recombinant urate oxidase (Elitekt), in the management of malignancy-associated hyperuricemia in pediatric and adult patients : final results of a multicenter compassionate use trial. Leukemia. 2005 ; 19 : 34-8.
 
7) Vadhan-Raj S, Fayad LE, Fanale MA, et al. A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome. Ann Oncol. 2012 ; 23 : 1640-5.
PubMed
8) Tamura K, Kawai Y, Kiguchi T, et al. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy : a phase III, randomized, multi-center trial comparing febuxostat and allopurinol. Int J Clin Oncol. 2016 ; 21 : 996-1003.
PubMed
9) Goldman SC, Holcenberg JS, Finklestein JZ, et al. A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. Blood. 2001 ; 97 : 2998-3003.
PubMed
10) Stapleton FB, Strother DR, Roy III S, et al. Acute renal failure at onset of therapy for advanced stage Burkitt lymphoma and B cell acute lymphoblastic lymphoma. Pediatrics. 1988 ; 82 : 863-9.
 
11) Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005 : a report from the children's oncology group. J Clin Oncol. 2012 ; 30 : 1663-9.
 
12) Atra A, Gerrard M, Hobson R, et al. Improved cure rate in children with B-cell acute lymphoblastic leukaemia (B-ALL) and stage IV B-cell non-Hodgkin's lymphoma (B-NHL) results of the UKCCSG 9003 protocol. Br J Cancer. 1998 ; 77 : 2281-5.
PubMed
13) Ishizawa K, Ogura M, Hamaguchi M, et al. Safety and efficacy of rasburicase (SR29142) in a Japanese phase II study. Cancer Sci. 2009 ; 100 : 357-62.
 
14) Sezer O, Vesole DH, Singhal S, et al. Bortezomib-induced tumor lysis syndrome in multiple myeloma. Clin Lymphoma Myeloma. 2006 ; 7 : 233-5.
PubMed
15) Oiwa K, Morita M, Kishi S, et al. High risk of tumor lysis syndrome in symptomatic patients with multiple myeloma with renal dysfunction treated with bortezomib. Anticancer Res. 2016 ; 36 : 6655-62.
PubMed
P.508 掲載の参考文献
1) Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol. 2007 ; 86 : 58-65.
PubMed
2) Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment : long-term results of the cooperative HLH-2004 study. Blood. 2017 ; 130 : 2728-38.
PubMed
3) 日本小児感染症学会, 監修. 木村宏他, 編集. 慢性活動性EBウイルス感染症とその類縁疾患の診療ガイドライン 2016. 東京 : 診断と治療社 ; 2016.
 
4) Marsh RA, Haddad E. How i treat primary haemophagocytic lymphohistiocytosis. Br J Haematol. 2018 ; 182 : 185-99.
 
5) Sin JH, Zangardi ML. Ruxolitinib for secondary hemophagocytic lymphohistiocytosis : First case report. Hematol Oncol Stem Cell Ther. 2017. Epub ahead of print.
 
6) Broglie L, Pommert L, Rao S, et al. Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv. 2017 ; 1 : 1533-6.
PubMed

VIII. 造血幹細胞移植

P.513 掲載の参考文献
1) 日本造血細胞移植学会. 平成29年度 全国調査報告書 日本造血細胞移植データセンター. http://www.jdchct.or.jp/data/report/2017/
 
2) Muffly L, Pasquini MC, Martens M, et al. Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. Blood. 2017 ; 130 : 1156-64.
PubMed
3) Heidenreich S, Ziagkos D, de Wreede LC, et al. Allogeneic stem cell transplantation for patients age > / =70 years with myelodysplastic syndrome : a retrospective study of the MDS subcommittee of the chronic malignancies working party of the EBMT. Biol Blood Marrow Transplant. 2017 ; 23 : 44-52.
 
4) Rashidi A, Ebadi M, Colditz GA, et al. Outcomes of allogeneic stem cell transplantation in elderly patients with acute myeloid leukemia : a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2016 ; 22 : 651-7.
PubMed
5) McClune BL, Weisdorf DJ, Pedersen TL, et al. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome. J Clin Oncol. 2010 ; 28 : 1878-87.
PubMed
6) Aoki J, Kanamori H, Tanaka M, et al. Impact of age on outcomes of allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in elderly patients with acute myeloid leukemia. Am J Hematol. 2016 ; 91 : 302-7.
PubMed
7) Hegde A, Murthy HS. Frailty : the missing piece of the pre- hematopoietic cell transplantation assessment? Bone Marrow Transplant. 2018 ; 53 : 3-10.
PubMed
8) Deschler B, Ihorst G, Schnitzler S, et al. Geriatric assessment and quality of life in older patients considered for allogeneic hematopoietic cell transplantation : a prospective risk factor and serial assessment analysis. Bone Marrow Transplant. 2018 ; 53 : 565-75.
PubMed
9) He F, Cao Q, Lazaryan A, et al. Allogeneic hematopoietic cell transplantation for older patients : prognosis determined by disease risk index. Biol Blood Marrow Transplant. 2017 ; 23 : 1485-90.
PubMed
10) Al Malki MM, Nathwani N, Yang D, et al. Melphalan-based reduced-intensity conditioning is associated with favorable disease control and acceptable toxicities in patients older than 70 with hematologic malignancies undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2018. Epub ahead of print.
 
P.519 掲載の参考文献
1) Fuji S, Inoue Y, Utsunomiya A, et al. Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality. J Clin Oncol. 2016 ; 34 : 3426-33.
PubMed
2) Bashey A, Medina B, Corringham S, et al. CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood. 2009 ; 113 : 1581-8.
PubMed
3) Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016 ; 375 : 143-53.
PubMed
4) Merryman RW, Kim HT, Zinzani PL, et al. Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphoma. Blood. 2017 ; 129 : 1380-8.
PubMed
P.524 掲載の参考文献
1) Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria : report on baseline data from the Chronic GVHD Consortium. Blood. 2011 ; 117 : 4651-7.
PubMed
2) Kurosawa S, Oshima K, Yamaguchi T, et al. Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017 ; 23 : 1749-58.
PubMed
3) Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015 ; 125 : 1333-8.
PubMed
4) Solomon SR, Sizemore C, Zhang X, et al. Current Graft-versus-Host Disease-Free, Relapse-Free Survival : A Dynamic Endpoint to Better Define Efficacy after Allogenic Transplant. Biol Blood Marrow Transplant. 2017 ; 23 : 1208-14.
PubMed
5) Kawamura K, Nakasone H, Kurosawa S, et al. Refractory graft-versus-host disease-free, relapse-free survival as an accurate and easy-to-calculate endpoint to assess the long-term transplant success. Biol Blood Marrow Transplant. 2018 ; 24 : 1521-6.
 
6) Fraser CJ, Bhatia S, Ness K, et al. Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors : a report from the Bone Marrow Transplant Survivor Study. Blood. 2006 ; 108 : 2867-73.
PubMed
P.530 掲載の参考文献
1) Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest. 2010 ; 120 : 4332-41.
PubMed
2) Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012 ; 55 :905-14.
PubMed
3) Jones JM, Wilson R, Bealmear PM. Mortality and gross pathology of secondary disease in germfree mouse radiation chimeras. Radiation Research. 1971 ; 45 : 577-88.
PubMed
4) van Bekkum DW, Roodenburg J, Heidt PJ, et al. Mitigation of secondary disease of allogeneic mouse radiation chimeras by modification of the intestinal microflora. J Natl Cancer Inst. 1974 ; 52 : 401-4.
PubMed
5) Storb R, Prentice RL, Buckner CD, et al. Graft-versus-host disease and survival in patients with aplastic anemia treated by marrow grafts from HLA-identical siblings. Beneficial effect of a protective environment. N Engl J Med. 1983 ; 308 : 302-7.
PubMed
6) van der Waaij D, Berghuis-de Vries JM, Lekkerkerk L-v. Colonization resistance of the digestive tract in conventional and antibiotic-treated mice. J Hyg (Lond). 1971 ; 69 : 405-11.
 
7) Jenq RR, Ubeda C, Taur Y, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012 ; 209 : 903-11.
PubMed
8) Gerbitz A, Schultz M, Wilke A, et al. Probiotic effects on experimental graft-versus-host disease : let them eat yogurt. Blood. 2004 ; 103 : 4365-7.
PubMed
9) Taur Y, Jenq RR, Perales MA, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014 ; 124 : 1174-82.
PubMed
10) Holler E, Butzhammer P, Schmid K, et al. Metagenomic analysis of the stool microbiome in patients receiving allogeneic stem cell transplantation : loss of diversity is associated with use of systemic antibiotics and more pronounced in gastrointestinal graft-versus-host disease. Biol Blood Marrow Transplant. 2014 ; 20 : 640-5.
PubMed
11) Jenq RR, Taur Y, Devlin SM, et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant. 2015 ; 21 : 1373-83.
PubMed
12) Peled JU, Devlin SM, Staffas A, et al. Intestinal microbiota and relapse after hematopoietic-cell transplantation. J Clin Oncol. 2017 ; 35 : 1650-9.
PubMed
13) Mathewson ND, Jenq R, Mathew AV, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 ; 17 : 505-13.
PubMed
14) Smith PM, Howitt MR, Panikov N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013 ; 341 : 569-73.
PubMed
15) Gupta VK, Paul S, Dutta C. Geography, ethnicity or subsistence-specific variations in human microbiome composition and diversity. Front Microbiol. 2017 ; 8 : 1162.
PubMed
16) Weber D, Oefner PJ, Dettmer K, et al. Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. Bone Marrow Transplant. 2016 ; 51 : 1087-92.
PubMed
17) Shono Y, Docampo MD, Peled JU, et al. Increased GVHD-related mortality with broad-spectrum antibiotic use after allogeneic hematopoietic stem cell transplantation in human patients and mice. Sci Transl Med. 2016 ; 8 : 339ra71.
PubMed
18) Weber D, Jenq RR, Peled JU, et al. Microbiota disruption induced by early use of broad-spectrum antibiotics is an independent risk factor of outcome after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2017 ; 23 : 845-52.
PubMed
19) Simms-Waldrip TR, Sunkersett G, Coughlin LA, et al. Antibiotic-induced depletion of anti-inflammatory clostridia Is associated with the development of graft-versus-host disease in pediatric stem cell transplantation patients. Biol Blood Marrow Transplant. 2017 ; 23 : 820-9.
PubMed
20) DeFilipp Z, Peled JU, Li S, et al. Third-party fecal microbiota transplantation following allo-HCT reconstitutes microbiome diversity. Blood Adv. 2018 ; 2 : 745-53.
PubMed
21) Kakihana K, Fujioka Y, Suda W, et al. Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood. 2016 ; 128 : 2083-8.
PubMed
P.537 掲載の参考文献
1) Murata M, Nakasone H, Kanda J, et al. Clinical factors predicting the response of acute graft-versus-host disease to corticosteroid therapy : an analysis from the GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2013 ; 19 : 1183-9.
 
2) MacMillan ML, Weisdorf DJ, Davies SM, et al. Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant. 2002 ; 8 : 40-6.
PubMed
3) Van Lint MT, Milone G, Leotta S, et al. Treatment of acute graft-versus-host disease with prednisolone : significant survival advantage for day+5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood. 2006 ; 107 : 4177-81.
PubMed
4) Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease : a phase II study. Lancet. 2008 ; 371 : 1579-86.
PubMed
5) Muroi K, Miyamura K, Okada M, et al. Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease : a phase II/III study. Int J Hematol. 2016 ; 103 : 243-50.
PubMed
6) Muroi K, Miyamura K, Ohashi K, et al. Unrelated allogeneic bone marrow-derived mesenchymal stem cells for steroid-refractory acute graft-versus-host disease : a phase I/II study. Int J Hematol. 2013 ; 98 : 206-13.
PubMed
7) Murata M, Ikegame K, Morishita Y, et al. Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD : an analysis of the JSHCT. Bone Marrow Transplant. 2017 ; 52 : 252-7.
PubMed
8) Socie G, Vigouroux S, Yakoub-Agha I, et al. A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. Blood. 2017 ; 129 : 643-9.
PubMed
9) 日本造血細胞移植学会. 造血細胞移植ガイドラインGVHD. 第4版. 2018.
 
10) Munneke JM, Spruit MJ, Cornelissen AS, et al. The potential of mesenchymal stromal cells as treatment for severe steroid-refractory acute graft-versus-host disease : A critical review of the literature. Transplantation. 2016 ; 100 : 2309-14.
PubMed
P.543 掲載の参考文献
1) Martin PJ, Counts GW Jr, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010 ; 28 : 1011-6.
PubMed
2) Gooley TA, Chien JW, Pergam SA, et al. Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2010 ; 363 : 2091-101.
PubMed
3) Pidala J, Anasetti C, Jim H, et al. Quality of life after allogeneic hematopoietic cell transplantation. Blood. 2009 ; 114 : 7-19.
PubMed
4) Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease : I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005 ; 11 : 945-56.
 
5) Cooke KR, Luznik L, Sarantopoulos S, et al. The Biology of Chronic Graft-versus-Host Disease : A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2017 ; 23 : 211-34.
PubMed
6) Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood. 2015 ; 125 : p.1333-8.
PubMed
7) Zeiser R, Blazar BR. Pathophysiology of chronic graft-versus-host disease and therapeutic targets. N Engl J Med. 2017 ; 377 : 2565-79.
PubMed
8) Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host Disease : I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant. 2015 ; 21 : 389-401.
 
9) 稲本賢弘. 移植後長期フォローアップと慢性GVHD. 日本造血細胞移植学会雑誌. 2017 ; 6. 84-97.
Medical*Online
10) Wolff D, Gerbitz A, Ayuk F, et al. Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD) : first-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant. 2010 ; 16 : 1611-28.
PubMed
11) Koc S, Leisenring W, Flowers ME, et al. Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000 ; 96 : 3995-6.
PubMed
12) Martin PJ, Storer BE, Rowley SD, et al. Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood. 2009 ; 113 : 5074-82.
PubMed
13) Miklos D, Cutler CS, Arora M, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017 ; 130 : 2243-50.
PubMed
14) Zeiser R, Burchert A, Lengerke C, et al. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation : a multicenter survey. Leukemia. 2015 ; 29 : 2062-8.
PubMed
15) Okamoto S, Teshima T, Kosugi-Kanaya M, et al. Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease. Int J Hematol. 2018. Epub ahead of print.
 
16) Koreth J, Kim HT, Jones KT, et al. Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease. Blood. 2016 ; 128 : 130-7.
PubMed
17) Williams KM, Cheng GS, Pusic I, et al. Fluticasone, azithromycin, and montelukast treatment for new-onset bronchiolitis obliterans syndrome after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016 ; 22 : 710-6.
PubMed
P.548 掲載の参考文献
1) Duval M, Klein JP, He W, et al. Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure. J Clin Oncol. 2010 ; 28 : 3730-8.
PubMed
2) Yamamoto H, Uchida N, Yuasa M, et al. A novel reduced-toxicity myeloablative conditioning regimen using full-dose busulfan, fludarabine, and melphalan for single cord blood Transplantation Provides Durable Engraftment and Remission in Nonremission Myeloid malignancies. Biol Blood Marrow Transplant. 2016 ; 22 : 1844-50.
PubMed
3) Mohty M, Malard F, Blaise D, et al. Sequential regimen of clofarabine, cytosine arabinoside and reduced-intensity conditioned transplantation for primary refractory acute myeloid leukemia. Haematologica. 2017 ; 102 : 184-91.
PubMed
4) Konuma T, Kato S, Ooi J, et al. Single-unit cord blood transplantation after granulocyte colony-stimulating factor-combined myeloablative conditioning for myeloid malignancies not in remission. Biol Blood Marrow Transplant. 2014 ; 20 : 396-401.
PubMed
5) Watanabe N, Takahashi Y, Matsumoto K, et al. Prognostic factors for outcomes of pediatric patients with refractory or relapsed acute leukemia undergoing allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant. 2011 ; 17 : 516-23.
PubMed
6) Ogawa H, Ikegame K, Daimon T, et al. Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR. Bone Marrow Transplant. 2018 ; 53 : 478-82.
PubMed
7) Decroocq J, Itzykson R, Vigouroux S, et al. Similar outcome of allogeneic stem cell transplantation after myeloablative and sequential conditioning regimen in patients with refractory or relapsed acute myeloid leukemia : A study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire. Am J Hematol. 2018 ; 93 : 416-23.
PubMed
8) Ringden O, Labopin M, Schmid C, et al. Sequential chemotherapy followed by reduced-intensity conditioning and allogeneic haematopoietic stem cell transplantation in adult patients with relapse or refractory acute myeloid leukaemia : a survey from the Acute Leukaemia Working Party of EBMT. Br J Haematol. 2017 ; 176 : 431-9.
PubMed
9) DeFilipp Z, Langston AA, Chen Z, et al. Does post-transplant maintenance therapy with tyrosine kinase inhibitors improve outcomes of patients with high-risk Philadelphia chromosome-positive leukemia? Clin Lymphoma Myeloma Leuk. 2016 ; 16 : 466-71.
PubMed
10) Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. Int J Hematol. 2018 ; 107 : 138-50.
PubMed
11) Oshikawa G, Kakihana K, Saito M, et al. Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol. 2015 ; 169 : 756-9.
PubMed
12) Mo XD, Lv M, Huang XJ. Preventing relapse after haematopoietic stem cell transplantation for acute leukaemia : the role of post-transplantation minimal residual disease (MRD) monitoring and MRD-directed intervention. Br J Haematol. 2017 ; 179 : 184-97.
PubMed
P.554 掲載の参考文献
1) Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990 ; 75 : 555-62. http://www.bloodjournal.org/content/75/3/555.abstract.
 
2) Appelbaum FR. Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL). Leukemia. 1997 ; 11 Suppl 4 : S15-7.
 
3) Grigg A, Ritchie D. Graft-versus-lymphoma effects : Clinical review, policy proposals, and immunobiology. Biol Blood Marrow Transplant. 2004 ; 10 : 579-90.
PubMed
4) Terwey TH, Le Duc TM, Hemmati PG, et al. NIH-defined graft-versus-host disease and evidence for a potent graft-versus-leukemia effect in patients with acute lymphoblastic leukemia. Ann Oncol. 2013 ; 24 : 1363-70.
PubMed
5) Kanda Y, Izutsu K, Hirai H, et al. Effect of graft-versus-host disease on the outcome of bone marrow transplantation from an HLA-identical sibling donor using GVHD prophylaxis with cyclosporin A and methotrexate. Leukemia. 2004 ; 18 : 1013-9.
PubMed
6) Kanda J, Morishima Y, Terakura S, et al. Impact of graft-versus-host disease on outcomes after unrelated cord blood transplantation. Leukemia. 2017 ; 31 : 663-8.
PubMed
7) Baron F, Labopin M, Niederwieser D, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia : A report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012 ; 26 : 2462-8.
 
8) Kanda J, Brazauskas R, Hu ZH, et al. Graft-versus-host disease after HLA-matched sibling bone marrow or peripheral blood stem cell transplantation : Comparison of North American Caucasian and Japanese Populations. Biol Blood Marrow Transplant. 2016 ; 22 : 744-51.
PubMed
9) Morishima Y, Kawase T, Malkki M, et al. Significance of ethnicity in the risk of acute graft-versus-host disease and leukemia relapse after unrelated donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 ; 19 : 1197-203.
 
10) Pidala J, Kurland B, Chai X, et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria : Report on baseline data from the chronic GVHD consortium. Blood. 2011 ; 117 : 4651-7.
PubMed
P.559 掲載の参考文献
1) Boeckh M, Gooley TA, Myerson D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation : a randomized double-blind study. Blood. 1996 ; 88 : 4063-71.
PubMed
2) Mori T, Mori S, Kanda Y, et al. Clinical significance of cytomegalovirus (CMV) antigenemia in the prediction and diagnosis of CMV gastrointestinal disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004 ; 33 : 431-4.
PubMed
3) 日本造血細胞移植学会ガイドライン委員会. 造血細胞移植ガイドライン ウイルス感染症の予防と治療. サイトメガロウイルス感染症. 第4版. (https://www.jshct.com/uploads/files/guideline/01_03_01_cmv04.pdf)
 
4) Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017 ; 377 : 2433-44.
PubMed
5) Gagelmann N, Ljungman P, Styczynski J, et al. comparative efficacy and safety of different antiviral agents for Cytomegalovirus prophylaxis in pllogeneic hematopoietic cell transplantation : a systematic review and meta-analysis. Biol Blood Marrow Transplant. 2018. pii : S1083-8791 (18) 30269-6.
 
6) Ahn H, Tay J, Shea B, et al. Effectiveness of immunoglobulin prophylaxis in reducing clinical complications of hematopoietic stem cell transplantation : a systematic review and meta-analysis. Transfusion. 2018. Epub ahead of print.
 
7) Takenaka K, Nishida T, Asano-Mori Y, et al. Cytomegalovirus reactivation after allogeneic hematopoietic stem cell transplantation is associated with a reduced risk of relapse in patients with acute myeloid leukemia who survived to day 100 after transplantation : The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group. Biol Blood Marrow Transplant. 2015 ; 21 : 2008-16.
 

書評

最近チェックした商品履歴

Loading...